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Abstract 
The skin is the largest organ of the human body and it constitutes a great protective barrier 
against entry of harmful microbial species and foreign materials into the body. The barrier 
function is a result of the highly hydrophobic nature and compact structure of the outermost 
skin layer, which makes transdermal delivery of drugs difficult. The aim of this study was to 
investigate diffusion of hydrophilic fish gelatin peptides and alginate oligomers (G-blocks) 
into human skin, and to evaluate the effect of skin pretreatments, vehicles and the different 
characteristics of the test samples on transdermal diffusion. 
Fish gelatin was degraded by acid hydrolysis to produce peptides of varying molecular size, 
and the molecular weight distribution and molecular weight averages of the peptides were 
determined. Further, peptides were conjugated to fluorescent dyes, and together with 
fluorescently labeled G-block oligomers, they were utilized as traceable model drugs in the 
transdermal diffusion experiments. Full-scale skins, from healthy human adults after 
abdominal plastic surgery, were used and the transdermal diffusion experiments were 
performed in Franz-type diffusion cells. The surface of the skin tissues mounted in the 
diffusion cells was either untreated or treated with micro-needles or lasers, to disrupt the skin 
barrier. The model drugs were applied on the epidermal side of the skins in both a 60% 
dimethyl sulfoxide (DMSO) and a 10% polyethylene glycol 200 (PEG200) vehicle, and the 
vehicles were also separately applied on skins as control samples. After the transdermal 
diffusion experiments, imaging of the skin tissues were performed by confocal laser scanning 
microscopy. 
An incubation time of 22 hours was determined for the transdermal diffusion experiments and 
pretreatments were necessary for the model drugs to successfully diffuse into the skin. 
Pretreatments with micro-needles and laser resulted in enhanced diffusion of the test 
molecules into the skin tissues compared to diffusion into untreated skin. Laser treatment was 
found to have the most profound enhancing effect on transdermal diffusion, and enabled 
efficient diffusion both into and through the skin. Of the four model drugs chosen for use in 
the experiments, the smallest fish gelatin peptide sample, with an estimated average molecular 
weight of 3000 g/mol, applied on skin tissues in a 10% PEG200 vehicle, showed the most 
efficient diffusion into and through human skin.            
  
iii 
 
Sammendrag  
Huden er kroppens største organ og utgjør en effektiv barriere som forhindrer at skadelige 
mikroorganismer og fremmed materiale kan gå inn i kroppen. Barrierefunksjonen er et 
resultat av den svært hydrofobe og kompakte strukturen i hudens ytterste lag, som gjør 
transdermal levering av legemidler vanskelig. Hensikten med dette studiet var å studere 
diffusjon av hydrofile fiskegelatinpeptider og alginatoligomerer (G-blokker) inn i hud fra 
mennesker, og å vurdere hvilken effekt forbehandlinger på huden, vehikler og de molekylære 
karakteristikkene til testmolekylene (f.eks. molekylvekt, ladning og amfifile/hydrofile 
egenskaper) har på transdermal diffusjon.       
Fiskegelatin ble degradert ved syrehydrolyse til peptider av ulik størrelse, og peptidenes 
molekylvektsfordeling og molekylvektsgjennomsnitt ble bestemt. Peptidene ble konjugert til 
fluorescerende fargestoffer, og ble benyttet som modeller for legemidler i de transdermale 
diffusjonsforsøkene, ettersom de kunne spores i hudvevet. Det ble brukt fullskala hud, fra 
friske voksne mennesker som hadde fått utført bukplastikk, i de transdermale 
diffusjonsforsøkene og forsøkene ble utført i diffusjonsceller (Franz-celler). Huden som ble 
montert i diffusjonscellene var enten ubehandlet eller forbehandlet med mikronåler eller laser, 
for å forstyrre hudbarrieren. Legemiddelmodellene ble påført på hudens epidermale side både 
i en 60% dimetylsulfoksid (DMSO) og en 10% polyetylen glykol vehikkel, og vehiklene ble i 
tillegg påført hudvevene som kontrollprøver. I etterkant av de transdermale 
diffusjonsforsøkene ble de ulike hudvevene studert ved hjelp av konfokal laser skanning 
mikroskopi.             
En inkubasjonstid på 22 timer ble bestemt for de transdermale diffusjonsforsøkene, og det ble 
funnet at forbehandling av hud var nødvendig for diffusjon av legemiddelmodellene inn i 
hudvevene. Sammenlignet med diffusjon inn i ubehandlet hud, førte forbehandling med både 
mikronåler og laser til økt diffusjon av legemiddelmodellene inn i hudvevene. Forbehandling 
med laser førte til størst økning i transdermal diffusjon, og gjorde det mulig for effektiv 
diffusjon både inn i og gjennom hud. Av de fire legemiddelmodellene som ble valgt for bruk i 
de transdermale diffusjonsforsøkene ble det minste fiskegelatin peptidet, med en 
gjennomsnittlig molekylvekt estimert til 3000 g/mol, påført huden i en 10 % PEG200 
vehikkel, funnet å diffundere raskest inn i og gjennom hud.         
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Symbols and abbreviations  
 
Alexa 488 HSS Alexa Fluor
®
 488 hydrazide, sodium salt 
Alexa 488 CASE Alexa Fluor
®
 488 carboxylic acid, succinimidyl ester 
Alexa 532 CASE Alexa Fluor
®
 532 carboxylic acid, succinimidyl ester 
Biopsy   Skin sample, tissue removed from a living body 
DMSO   Dimethyl sulfoxide  
DOL   Degree of labeling 
EtOH   Ethanol 
FHMW   Fraction of high molecular weight 
FLMW   Fraction of low molecular weight 
1
H-NMR  
1
H-Nuclear Magnetic Resonance Spectroscopy 
Iauto   Tissue autofluorescence given as Imean-control ± SD 
Icorrected Mean fluorescence intensity in the tissue corrected for DOL, Icorrected ± 
SD 
Imean-control  Mean fluorescence intensity in the control tissue, given as Imean-control ± 
SD   
Imean-sample  Fluorescence intensity in the tissue only due to transdermal diffusion of   
fluorescently labeled sample, given as Imean-sample ± SD 
Imean-tissue Fluorescence intensity in the tissue due to both trandermal diffusion of 
fluorescently labeled sample and tissue autofluorescence, given as Imean-
tissue ± SD 
IRP   Fluorescence intensity in the receptor phase 
IRP corrected  Fluorescence intensity in the receptor phase corrected for DOL 
KCl   Potassium chloride  
KH2PO4  Potassium phosphate monobasic  
LSCM   Laser Scanning Confocal Microscopy 
λemission   Fluorescence emission maxima (nm) 
vii 
 
λmax Absorption/Excitation maxima (nm) 
MALDI-TOF  Matrix Assisted Laser Desorption-Ionization – Time-Of-Flight 
MWCO  Molecular Weight Cut-Off 
NaCl   Sodium chloride 
Na2HPO4 ∙2H2O di-Sodium hydrogen phosphate dehydrate  
NaHCO3  Sodium bicarbonate 
PBS   Phosphate buffered saline 
PEG200  Polyethylene glycol 200 
SC   Stratum Corneum 
SD   Standard Deviation 
SEC-MALLS  Size Exclusion Chromatography - Multi-Angle Laser Light Scattering 
µS   Microsimens, unit of measurement for the conductivity of water 
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1. Introduction 
1.1. Aim of the study 
The skin is the most accessible organ of the human body and provides a possibility for 
delivery of drugs for both local and systemic effect. The field of transdermal drug delivery 
has received increasing interest due to the advantages associated with this route of 
administration. However, the highly hydrophobic nature of the protective skin barrier limits 
transdermal delivery of a wide range of drugs, especially large and hydrophilic drug 
molecules.  
In this study the primary aim was to investigate the diffusion of hydrophilic molecules into 
human skin and the potential effects of physical penetration enhancement, chemically 
enhancing vehicles, and the molecular and structural characteristics of the applied molecules, 
such as molecular weight, chain conformation, amphiphilic/hydrophilic properties, and 
charge. Fish gelatin peptides and G-block oligomers of alginate were used as test molecules in 
the experiments performed to study transdermal diffusion. The test molecules were chosen for 
their varying physicochemical properties, and because they could act as model drugs for a 
range of hydrophilic drugs based on peptides/proteins and polysaccharides.  
The secondary aims of this study included molecular characterization of fish gelatin peptides, 
performance of a pilot study to evaluate the effect of three different laser treatments in regards 
to both enhancing effect and skin damage and viability, and a study of diffusion kinetics in 
human skin. 
1.2. The human skin 
In simplicity, the skin can be described as the organ keeping the “inside in and the outside 
out” of the human body.  The human skin covers an average area of 1.7 m2, it constitutes 10% 
of the body mass of an average human being, and is considered to be the largest and heaviest 
organ of the body (Williams, 2003, Schrieber and Gareis, 2007). The skin functions as an 
acidic mantle, and has a natural microbial flora, comprising transient, temporary-resident and 
permanent-resident microbial species. The composition and density of this flora is 
predominantly pH-dependent. The acidic surface supports the persistence of a normal 
microbial flora, but limits colonization by pathogenic microbes, and thus prevents entry of 
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such harmful species into the body (Fluhr et al., 2005, Schrieber and Gareis, 2007). The skin 
barrier also protects and helps the human body to withstand cold, heat, radiation, external 
pressure, physical and mechanical injuries, friction and chemicals. It regulates body heat, 
prevents loss of moisture, and has a major function as a sensory organ (Schrieber and Gareis, 
2007). In addition, vitamin D is synthesized in the human skin (Wickett and Visscher, 2006). 
1.2.1. Structure of the skin 
Healthy human skin can be divided into three main layers: hypodermis (subcutaneous fat 
layer), dermis (corium) and epidermis (cuticle) (Figure 1.1) (Schrieber and Gareis, 2007, 
McGrath et al., 2010).  
 
Figure 1.1: The structure of the skin including the three main skin layers: hypodermis, dermis 
and epidermis (Mitchell and Peel, 2009). 
The hypodermis is located between underlying body constituents, such as muscles, bone, fat 
or cartilage, and the overlying dermis (Williams, 2003, Schrieber and Gareis, 2007). This 
subcutaneous layer consists of fat pads, closely packed fat cells, surrounded by a loose 
connective tissue. Fibers which origin in the dermis span the subcutaneous layer and are in 
direct contact with collagen fibers underlying the sub-cutis (Schrieber and Gareis, 2007). The 
thickness and structure of the hypodermis varies between individuals, in regards to body site, 
gender and amount of body fat (Faller et al., 2004, Song et al., 2004). The hypodermis is 
absent in some areas of the body, such as the eyelids, but mostly it constitute a thick layer in 
scale of millimeters to centimeters throughout the body (Williams, 2003, Song et al., 2004). 
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The subcutaneous layer can act as insulation against cold and heat, and as a supply of high-
energy molecules. It also provides mechanical protection against physical injuries, and carries 
blood-vessels and nerve cells to the skin (Williams, 2003, Schrieber and Gareis, 2007).       
The dermis is located between the hypodermis and the epidermis, and constitutes the major 
component of the human skin. The dermis exists of two layers, the deeper reticular dermis and 
the outer papillary dermis (MacKie, 2003). The reticular dermis is characterized by its 
irregular, dense and collagen rich connective tissue, and this layer attaches the skin to the 
underlying hypodermis. The papillary layer consists of a characteristic loose connective tissue 
that contains collagen, reticulin (a structural protein resembling collagen), elastin and 
fibroblasts, and it connects the epidermis to the dermis. There are less abundant cells in the 
reticular dermis compared to in the papillary dermis (Mitchell and Peel, 2009).       
Fibroblasts, macrophages, and mast cells are the three main cell types comprising the cellular 
components of the dermis (MacKie, 2003, McGrath et al., 2010). There is a rich blood supply 
to the dermis, but no blood vessels intersect the junction between the dermis and the 
epidermis (McGrath et al., 2010). The dermal vasculature supplies the dermis with oxygen 
and nutrients, removes toxins and waste products, and plays a vital role in the regulation of 
body temperature (Williams, 2003). In addition to blood vessels, lymphatic vessels, nerve 
endings, and the skin appendages, including hair follicles, sebaceous glands, and sweat glands 
are embedded in the dermis (MacKie, 2003, Williams, 2003).  
The epidermis is the outermost layer of the human skin. The thickness of the layer varies from 
roughly 0.006 mm (eyelid) to 0.08 mm (palms and soles) (Aulton, 2007). It is a stratified, 
squamous and terminal keratinized epithelium, where the majority of cells, making up 95% of 
the total cell content, are the keratinocytes in the viable epidermis and the corneocytes in the 
non-viable epidermis (Mitchell and Peel, 2009, McGrath et al., 2010). Other cells are also 
located in the epidermis, such as melanocytes (pigment producing cells), Merkel cells 
(mechanoreceptors), and Langerhans cells (dendritic and immunological competent cells) 
(Williams, 2003, MacKie, 2003, Mitchell and Peel, 2009). The keratinocytes travel from the 
epidermal basement membrane and outwards to the surface, forming distinct layers 
throughout the epidermis. From the lower dermal-epidermal interface and towards the outer 
surface of the skin, the epidermis can be separated into five distinct layers: stratum 
basale/stratum germinativum, stratum spinosum, stratum granulosum, stratum lucidium and 
stratum corneum (McGrath et al., 2010). All layers are only present in body areas where the 
skin is considered to be thick (Mitchell and Peel, 2009). In transit, from the basal layer and 
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outwards to the stratum corneum (SC), the keratinocytes undergo a series of biochemical and 
morphological changes, including nuclei and organelle disintegration, and replacement of the 
cell membranes with cell envelopes of cross-linked proteins. These changes leads to the 
production of dead, flattened and enucleated keratinocytes, called corneocytes, which 
constitute the stratum corneum (SC). Overall, the continuous transformation of keratinocytes 
to corneocytes takes 28 days (Williams, 2003, Wickett and Visscher, 2006, Mitchell and Peel, 
2009).  
The stratum corneum is the last and outermost layer of the epidermis, and is a thin and non-
viable membrane typically consisting of 10-15 layers of corneocytes (Williams, 2003, Benson 
and Namjoshi, 2008). The structure of the SC is often represented as a “brick and mortar” 
model. The keratin-filled corneocytes constitute the bricks, and are connected to one another 
through corneosomes, which originates from desmosomes (cellular bridges) in the viable 
epidermis. The lipid matrix in the intercellular space surrounding the corneocytes is the 
mortar. This matrix consists of ceramides (≈50%), cholesterol (25%), free fatty acids (10-
12%) and a small moiety of cholesterol sulfate (≈5%) and cholesterol esters (≈2%) organized 
in multiple bilayers. The lipid composition in the SC is different from the one found in the 
underlying viable epidermis, primarily consisting of phospholipids (Downing, 1992, 
Williams, 2003, Wickett and Visscher, 2006, Benson and Namjoshi, 2008). The constituents 
of the mortar comprise a lipid lamellae consisting of both crystalline and liquid domains. The 
combination of the corneocyte structure and the hydrophobic lipid composition form a 
flexible and excellent protective barrier in healthy human skin (Bouwstra et al., 2002, Wickett 
and Visscher, 2006).  
Water also plays an important role in maintaining the integrity of the SC barrier. The 
continuous desquamation, or shedding, of old corneocytes from the skin surface is dependent 
on the activity of hydrolytic enzymes. The activity of the enzymes is further affected by the 
humidity in their surroundings. Thus, water is essential for the degradation of 
corneodesmosomes leading to detachment and shedding of corneocytes. The water activity of 
keratinocytes also regulates enzymes involved in the formation of natural moisturizing factor 
(NMF), which is the skin’s natural hydration mechanism located in the SC. NMF consist of a 
hygroscopic mixture of roughly 50 % amino acids and 50 % salts, including lactic acid and 
urea. As a result of its composition, NMF function as a water-binding mechanism in the SC 
and assist in the maintenance of skin elasticity. A hydrated SC also reduces the risk of skin 
cracking (Williams, 2003, Draelos, 2005).  
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1.3. Transdermal administration of drugs 
The transdermal route of drug administration presents an appealing alternative to other drug 
delivery routes. Today around 35 transdermal drug products, comprising around 20 drug 
molecules, are on the market. An increase in both the development of new products and the 
value on the global market is expected (Tanner and Marks, 2008, Subedi et al., 2010). The 
transdermal administration route can be used for delivery of drugs for both local effect, such 
as local pain relief (e.g. Ibux), and systemic effect (Thomas and Finnin, 2004, Weifa, 2012). 
Transdermal delivery of drugs to the systemic circulation offers a series of advantages 
compared to its administration counterparts. Orally delivered drugs are observed to cause 
gastrointestinal irritation, and during delivery the drugs are affected by variables such as 
enzymes, pH and gastric emptying. In addition, the liver contributes to the first pass 
metabolism of the drugs. Drugs delivered by the transdermal route avoid the gastrointestinal 
tract and are exposed to reduced first pass metabolism. Transdermal delivery potentially 
improves patient compliance, as a result of painless and easy treatment (in contrast to 
hypodermic injections or tablets). Other benefits with this route of administration are 
controlled and sustained delivery, reduced frequency and amount of dose, which conduce to a 
reduced risk of side effects, and the possibility of immediately and easy termination of 
treatment (Prausnitz et al., 2004, Thomas and Finnin, 2004, Tanner and Marks, 2008, Subedi 
et al., 2010). However, despite the great advantages of transdermal drug delivery there are 
few available products, which reflect the limitations associated with this route of 
administration, as will be described later in this section.   
In transdermal drug delivery the drugs applied on the skin have three possible penetration 
routes. The molecules can penetrate 1) through the sweat ducts, 2) across the stratum corneum 
or 3) via the hair follicles and their associated sebaceous glands (Figure 1.2) (Benson and 
Namjoshi, 2008). The appendages only comprise about 0.1 % of the area available for 
transdermal penetration and are therefore generally considered as negligible (Barry, 2001, 
Benson and Namjoshi, 2008).      
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Figure 1.2: In transdermal drug delivery the drugs applied on the skin have three possible 
penetration routes: through the sweat ducts (1), across the stratum corneum (2) or via the hair 
follicles and their associated sebaceous glands (3) (Benson, 2005).     
The penetration route across the SC can be divided into the transcellular route and the 
intercellular route (figure 1.3). The transcellular route is considered unfavorable because the 
drugs not only have to partition and diffuse through the corneocytes, they also have to 
traverse to adjacent corneocytes through the intercellular lipid matrix (Benson, 2005). This 
suggests that the intercellular route is the predominant route of penetration across the SC, 
which provides a tortuous path of diffusion much longer (500 µm) than the thickness of SC 
(Hadgraft, 2004, Benson and Namjoshi, 2008). After overcoming the SC barrier drug 
molecules must diffuse deeper into viable epidermis to reach the vasculature in the dermis, 
and hence the systemic circulation. Small and moderately lipophilic molecules overcome the 
SC and can continue their diffusion into the deeper skin layers. For hydrophilic and high 
molecular weight drug molecules, such as proteins and peptides, the ability to diffuse through 
viable epidermis and into the dermis are solely restricted by the outermost barrier of SC 
(Benson and Namjoshi, 2008, Karande and Mitragotri, 2009, Kalluri and Banga, 2011). 
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Figure 1.3: A simple illustration of the intercellular and the transcellular penetration routes 
across the SC barrier (Florence and Attwood, 2006).  
There are several factors that influence the rate of transdermal drug delivery to and through 
healthy human skin. Physicochemical factors include the chemistry of the drug, skin 
hydration, temperature and pH, drug concentration, and molecular size and shape. 
Physiological factors include skin condition, skin metabolism, skin age and sites of drug 
application (Williams, 2003, Aulton, 2007). The hydrophobic layer of stratum corneum is 
considered to be the rate limiting step in transdermal drug delivery. For a molecule to 
passively diffuse and partition across the barrier, it must possess several physical and 
chemical properties. Only pharmacologically potent and low molecular weight compounds 
(<500 Da) with low melting points (>200˚C), and moderate lipophilicity and water solubility 
are allowed to passively move across the SC (Benson and Namjoshi, 2008, Kalluri and Banga, 
2011). In regards to molecular size, it has been shown a correlation between molecular size 
and skin absorption, and  for molecular weights above 500 Dalton (Da) absorption starts to 
rapidly decrease (Bos and Meinardi, 2000). Local skin irritation and additional adverse 
effects, caused by the drugs, excipients or components associated with the delivery devices, 
and delay in onset of action, are associated with this route of delivery. The limited drug doses 
that can be applied are also a disadvantageous and limiting factor in transdermal drug delivery 
(Brown et al., 2006, Tanner and Marks, 2008).     
Intact and healthy skin holds the strong barrier of SC. However, skin disorders can affect the 
permeability of the barrier and in diseases where SC is defect, absorption will tend to 
increase. An increase in absorption can also be a result of physical injuries, such as cuts and 
abrasions (Aulton, 2007). Skin age show little difference in transdermal drug delivery, but 
both structural and functional alterations occur with aging. The moisture content of the skin is 
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known to decrease with age and therefore younger and more hydrated skin is more permeable 
compared to older skin. Blood flow also tends to decrease with age and can further reduce the 
transdermal flux of topically applied drugs (Williams, 2003). The thickness and nature of  the 
SC and density of body appendages varies throughout the human body. Differences in 
permeation occur both between different body sites of an individual and between identical 
body sites in different individuals, illustrating that permeation is not only affected by the 
thickness of the SC (Williams, 2003, Aulton, 2007, Tanner and Marks, 2008). Race, gender 
and amount of body fat may also contribute to variation in drug absorption and transdermal 
drug delivery among individuals (Williams, 2003, Robinson, 2005).  
For drug molecules unable to passively diffuse through the SC, a possibility is to increase skin 
permeability by chemical, enzymatic or physical modifications. The challenge is to modify 
SC in a safe and reversible fashion to avoid permanent skin damage or introduction of 
pathogens to the body (Karande and Mitragotri, 2009, Pathan and Setty, 2009). Penetration 
enhancement techniques can be divided into chemical and physical methods (Karande and 
Mitragotri, 2009, Subedi et al., 2010). Chemical methods include prodrugs, salt formation, ion 
pairs, eutectic systems, liposomes, vesicles and particles, and the use of chemical enhancing 
vehicles and other chemical enhancers (Benson, 2005, Subedi et al., 2010). For both lipophilic 
and hydrophilic drugs water is the most natural and safe penetration enhancer, and in addition 
to altered solubility of the drug and partitioning from the vehicle, it is a possibility that 
hydration of the skin results in increased penetration due to swelling and opening of the SC 
(Benson, 2005). Skin hydration can be increased by the use of occlusive dressings, which 
lower the transepidermal water loss and increase the skins capacity of water holding 
(Praessler and Fluhr, 2005).   
Chemical enhancers reduce the barrier properties and increase the permeability by altering the 
structure of the intercellular lipid matrix in the SC (Kalluri and Banga, 2011, Karande and 
Mitragotri, 2009). Chemical enhancers can be grouped into hydrocarbons, alcohols, acids, 
amines, amides, esters, surfactants, terpenes, sulfoxides, lipids and miscellaneous complexes. 
Polyethylene glycol (PEG) is a solvent in the group of alcohols that has been found to 
increase skin permeability. Alcohols may enhance skin diffusion through different 
mechanisms, including extraction of lipids, swelling of the SC or improving drug partitioning 
into the skin (Karande and Mitragotri, 2009). PEG is non-toxic and non-immunogenic, and is 
known to have an amphiphilic nature, which makes the polymers soluble both in water and 
organic solvents. Further, it is widely used in pharmaceutical formulations such as oral 
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solvents in liquid-filled capsules, and dermal ointments and creams (Barnes et al., 2008). The 
aprotic solvent dimethyl sulphoxide (DMSO), which tends to form hydrogen bonds with itself 
rather than with water, is considered to be a “universal solvent” (Pathan and Setty, 2009). 
DMSO increases the lipid fluidity, and hence the permeability of SC due to the alterations in 
the lipid matrix, and is found to enhance penetration of both hydrophilic and hydrophobic 
molecules. This solvent is concentration-dependent and to achieve optimal penetration 
enhancement, concentrations of > 60% is required (Williams and Barry, 2004, Notman et al., 
2007, Pathan and Setty, 2009). The high concentration dependency of DMSO can, however, 
cause skin irritation and cutaneous eruptions (Williams and Barry, 2004, Benson, 2005, 
Pathan and Setty, 2009).   
Physical penetration enhancement methods disrupt the skin barrier, and include the use of 
micro-needles, iontophoresis, electroporation, sonophoresis, jet injectors, lasers, thermal and 
radiofrequency ablation, and ablation by tape stripping. Both chemical enhancers and physical 
methods act individually, but they can also be combined to produce a synergistic 
enhancement effect (Benson, 2005, Karande and Mitragotri, 2009, Kalluri and Banga, 2011). 
Physical penetration enhancement techniques based on micro-needles and laser treatment 
were of particular interest in this study.    
1.3.1.  Micro-needles 
Micro-needles are a minimally invasive technique where needles in the size range of microns 
create channels or holes in the skin/SC, through which skin-impermeant molecules can be 
transported (Prausnitz, 2004, Kalluri and Banga, 2011). Micro-needle devices consist of a 
plurality of needles with a general length range from 25-2000 µm attached to a base support 
(Donnelly et al., 2010). The micron-sized pores created by micro-needles can allow for 
transport of macromolecules, supramolecular complexes and micro-particles across the SC 
barrier and into deeper layers of the skin (Prausnitz, 2004). Micro-needles can either be 
categorized as solid or hollow. Solid micro-needles can be utilized either to porate the skin 
before a drug molecule is applied or can be coated with the drug prior to poration (Figure 1.4a 
and b). Hollow micro-needles can be used to infuse or inject a liquid drug formulation (Figure 
1.4c). Another possibility is to encapsulate the drug in biodegradable micro-needles that will 
dissolve and release the drug in the skin after poration (Figure 1.4d) (Benson and Namjoshi, 
2008, Kalluri and Banga, 2011). Perforation by micro-needles, followed by removal of the 
device results in higher skin permeability compared to micro-needles that remain in the skin. 
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This is probably due to a blockage of the pores, either by the supporting material from which 
the needles project or by the needles themselves (Henry et al., 1998). A drawback associated 
with micro-needles is the limited amount of dose that can be coated on solid micro-needles or 
loaded in biodegradable micro-needles (Kalluri and Banga, 2011).      
 
 
Figure 1.4: A schematic overview of micro-needle design and mode of application in 
transdermal drug delivery: a) Solid micro-needles porate the skin prior to drug application, b) 
solid micro-needles coated with drug prior to skin poration, c) biodegradable micro-needles 
with encapsulated drug that dissolve and release the active substance in the skin, d) hollow 
micro-needles that infuse or inject the drug (Escobar-Chavez et al., 2011).    
During poration of the skin, small micro-needles avoid the nerves and blood vessels found in 
deeper layers of the skin and are therefore not associated with pain, and cause minimal skin 
irritation. This is because they generally only penetrate the SC and the epidermis (Henry et 
al., 1998, Kaushik et al., 2001, Bal et al., 2008). Though, the needles penetrating the skin may 
also be inserted into both the epidermis and the superficial layers of the dermis, depending of 
the micro-needle device used. The painless conception of micro-needles can therefore also be 
explained by the reduced risk of the small needles to encounter nerves and stimulate a 
response causing pain (Prausnitz, 2004). However, micro-needle devices consisting of longer 
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needles, such as the one used in this study (1500 µm), reach deeper into the skin and increases 
the risk of pain and damage of blood capillaries, causing bleeds (Badran et al., 2009).  
The use of micro-needles in transdermal drug delivery gives rise to different safety concerns. 
The risk of needle fracture in the skin indicates a need for micro-needles with appropriate 
geometry and physical properties. Micro-needles with a safety margin value, defined as the 
ratio between the fracture force and the insertion force, greater than one, will not fracture 
when inserted into the skin. Needles with a small tip radius strengthen by a thick wall achieve 
the highest safety margin values (Prausnitz, 2004). In addition sterility and time until pore 
closure is important parameters affecting the possibilities of skin infections and irritation 
(Kalluri and Banga, 2011). The pore size after micro-needle perforation decreases with time 
and for the method to be fully reversible the pores must eventually be closed (Badran et al., 
2009). Recovery of the barrier function of SC in the micro-pores is reported to occur as early 
as 2 hours after poration in absence of occlusion. Resealing of micro-pores in occluded sites 
ranges from 3-40 hours, depending on the geometry of the utilized micro-needles (Gupta et 
al., 2011). Others have reported evidence of repair and pore closure after 8-24 hours (Haq et 
al., 2009). 
Micro-needle based applicator designs exist on the market, including different micro-needle 
patches utilizing the different designs and application modes given in Figure 1.3. These 
patches differ from the traditional patch delivery systems because they require external energy 
or pressure to ensure sufficient and desired depths of penetration through the skin barrier. 
Applicator devices, providing consistent penetration, or manual application methods can be 
used for this purpose. However, consistent depths of penetration and constant pressure are 
more difficult to obtain with manual methods of application. Micro-needle rollers (MTS-
Rollers
TM
, Dermaroller
®
) are available in different models for both personal and clinical use, 
and are primarily developed for cosmetical and dermatological applications (Donnelly et al., 
2010). Due to the already existing market of micro-needle based technology and its promising 
prospects in transdermal drug delivery, a micro-needle device of the type Dermaroller
®
 
(Dermaroller LLC, USA) was chosen as a physical enhancement method in this study.  
1.3.2. Laser treatment  
Lasers are widely used in the treatment of dermatological conditions and in cosmetic 
resurfacing of the skin, and include treatment of acne, acne scars, aging, photodamage, 
depigmentation, wrinkles and general smoothing of the skin (Fernandes, 2005, Brown et al., 
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2006, Benson and Namjoshi, 2008). In laser treatment high energy laser beams are directly 
applied on the skin and results in controlled ablation of the SC. The heat generated at the skin 
surface cause a rapid evaporation of water molecules and formation of vertical holes in the 
size range of microns, functioning as channels through SC and into deeper skin layers of the 
skin (Brown et al., 2006, Benson and Namjoshi, 2008). A laser can create a pattern of 
multiple spots or channels through skin, where only a fraction of the treated area is damaged 
and surrounded by intermediate undamaged and unexposed skin. This can be described as 
ablative fractional resurfacing, and both CO2 and low intensity erbium YAG (yttrium-
aluminum-garnet) lasers are utilized (Hædersdal et al., 2010).  
In addition to skin treatment, laser ablation is suggested as a possible physical penetration 
enhancement method in transdermal drug delivery (Benson and Namjoshi, 2008, Kalluri and 
Banga, 2011). Laser treatment increases the skin permeability of both hydrophilic and 
lipophilic drugs. However, a more significant increase in the permeation of hydrophilic drugs 
compared to lipophilic drugs has been found, indicating a correlation between the chemical 
nature of the drug molecule and the impact of the SC barrier on transdermal drug delivery 
(Lee et al., 2001). Different parameters, such as the wavelength of the laser light emitted, 
pulse energy applied, laser power, duration of radiation, pulse repetitions, spot size and 
number and density of spots, influence the degree of barrier disruption (Lee et al., 2001, 
Brown et al., 2006, Hædersdal et al., 2010). The advantages of laser treatment in drug 
delivery are reported to be the short treatment time, controlled removal of tissue, minor 
adverse effects and minimal pain (Brown et al., 2006). However, laser treatments used in 
dermatology are basically described as burns, which can cause a variety of adverse effects. 
These effects include pain, persistent redness, blistering (edema), infections and pigment 
changes (Gold, 2010). The high costs apparatus and need for expert operation to minimize 
safety risks such as burns, restricts the use of laser to clinical settings. In terms of transdermal 
drug delivery this means a poor patient compliance when it comes to self administration and 
home use (Barry, 2001).  
Laser treatment was included in this study only to provide a standardized method to penetrate 
human skin. This standardization was of great value in studying the transdermal diffusion of 
hydrophilic molecules through human skin from different donors. The treatment provided 
identical patterns of laser spots, including identical laser spot density, distance between spots, 
and spot depth and diameter at the site of application of test molecules.     
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1.4. Diffusion through skin 
For a topically applied drug to act either locally or systematically it must penetrate the SC 
barrier of the skin (figure 1.3). The SC is a passive diffusion barrier that show no evidence of 
metabolic transport processes (Florence and Attwood, 2006). Passive diffusion occurs when 
matter moves from one region of a system to another through random molecular motion. The 
diffusion of isotropic materials, materials with identical structural and diffusional properties 
in all directions, can be described by Fick’s first law of diffusion (Equation 1.1) (Aulton, 
2007). 
  
C
J D
x

 

          (1.1) 
In the equation, J is the flux of the drug, D is the diffusion coefficient, C is the concentration 
and x is the measured diffusion distance. The negative sign indicates that the flux moves 
down the concentration gradient, thus in the direction of decreasing concentration (Aulton, 
2007). Passive diffusion of water and non-electrolytes of low molecular weight through the 
epidermis is proportional to concentration and the solute partition coefficient between the 
tissue and the vehicle. Steady state transport through the skin can be described by the form of 
Fick’s first law given in Equation 1.2 (Florence and Attwood, 2006). 
v
DP
J C
 
  
 
         (1.2)   
Here, P is the partition coefficient of the solute between the vehicle and the skin, δ is the 
thickness of SC and ΔCv is the concentration difference between the vehicle and the tissue 
(Florence and Attwood, 2006). The drug diffusion coefficient in the skin will be determined 
by physicochemical factors such as molecular size, shape and charge, and the partitioning 
coefficient will be determined by the properties of both the drug and the vehicle used. 
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1.5. Biopolymers as model drugs and potential candidates for 
transdermal drug delivery 
Polymers are macromolecules built up from small residues called monomers. A molecule is 
commonly regarded as an oligomer if it contains 2-20 such monomer residues and as a 
polymer if the molecules contain >20 monomers and have a molecular weight above 10000 
g/mol. Biopolymers are biologically occurring polymers, and the most important biopolymers 
are normally divided into nucleic acids and nucleotides, proteins and amino acids, 
carbohydrates and lipids. Biopolymers can also be divided either by their chemical properties 
or their function (Smidsrød and Moe, 2008).   
Proteins and peptides are polymers constructed from 20 different amino acids. The amino 
acids are linked together through peptide bonds between the α-carboxyl group of one amino 
acid and the α-amino group of another. The amino acid composition and sequence of proteins 
and peptides determine their properties and function. Peptides can be regarded as fragments of 
larger proteins or polypeptides obtained by cleavage of peptide bonds in the amino acid 
sequence (Nelson et al., 2008). The amino acids, and thus proteins and peptides, have 
zwitterionic nature, which means that they contain both positive and negative charges at 
physiological pH. This feature strongly affect their physical properties (Smidsrød and Moe, 
2008). Proteins and peptides are approved for medical use and are classified as 
biopharmaceuticals (Benson and Namjoshi, 2008, Antosova et al., 2009). Drugs based on 
proteins and peptides are predominantly delivered through the parenteral route (injections and 
intravenous infusion). This route is disadvantageous due to a need for repeated administration 
and low patient compliance (Kalluri and Banga, 2011). Transdermal delivery (section 1.3) has 
therefore been suggested as an attractive alternative. 
Proteins and peptides are generally high molecular weight molecules with amphiphilic, 
hydrophilic, and/or charged nature (Benson and Namjoshi, 2008). A consequence of this is 
poor permeation through the skin barrier and the need for penetration enhancement techniques 
to overcome the skin barrier, as described in section 1.3. A majority of proteins and peptides 
are intended for systemic effect. However, administration through the transdermal route to 
target sites in the skin also provides a great potential for local therapeutic effect (Benson and 
Namjoshi, 2008, Namjoshi et al., 2008). In this study, fish gelatin peptides, representing 
peptides in general, were utilized as model drugs.  
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Polysaccharides are biopolymers built up by monosaccharide residues linked together by 
glycosidic linkages. They have diverse chemical structures, giving rise to diverse properties, 
as polysaccharides differ from each other in the identity of their repetitive monosaccharide 
residues, chain length, types of glycosidic bonds in the polysaccharide chain and degree of 
branching (Smidsrød and Moe, 2008, Nelson et al., 2008). In this study, oligomers of the 
polysaccharide alginate were also utilized as hydrophilic model drugs in this study.  
1.5.1.  Fish gelatin – an amphiphilic model drug 
Gelatin in general is a very versatile biopolymer derived from the fibrous protein collagen, the 
most abundant protein found in animals (Veis, 1964, Babel, 1996). Collagen is the major 
component of connective tissues and bones, and its molecular structure is made up by three 
parallel α-chains that constitute a right-handed triple helical rod. The three α-chains have the 
general amino acid sequence Gly-X-Y, where X often is proline (Pro) and Y often is 
hydroxyproline (Hyp), but yet each chain in a collagen molecule have a singular amino acid 
composition (Haug and Draget, 2009, Eysturskaro et al., 2009). The imino acids proline and 
hypdroxyproline cause a left-handed helical structure. Hydrogen bonds stabilize the collagen 
triple helix, and covalent cross-linking between the three α-chains gives collagen its super-
helical structure. Gelatin is derived from collagen through partial hydrolysis and gives rise to 
a polydisperse gelatin product (Haug et al., 2004, Eysturskard et al., 2009).  
The raw material sources for gelatin production can be mammalian sources, such as bovine or 
porcine, or marine sources, including both warm and cold water fish species (Haug and 
Draget, 2009). Gelatin (mainly mammalian) is utilized in a variety of applications in the food, 
pharmaceutical, medical and cosmetic industries, reflecting their diverse properties and their 
non-toxic and biodegradable nature (Haug and Draget, 2009). Gelatins from marine sources 
are suggested as potential alternatives to mammalian gelatins and they have several appealing 
advantages. Utilization of marine gelatins is not associated with the risk of “mad cow disease” 
(bovine spongiform encephalopathy, BSE), and their use are in fully acceptance with Islam 
and minimally restricted by other religions compared to bovine and porcine gelatins. The 
fishery industry generates a large biomass of fish waste that, rather than being discarded, can 
serve as a rich marine sources for fish gelatin. Thus, fish gelatin can be provided at low costs 
(Karim and Bhat, 2009). Other factors, however, restrict the range of use of fish gelatin in 
industrial applications, such as low manufacturing efficiency, due to low concentrations of 
collagen in fish skin. Fish gelatin may also be a potential allergen, and they have physical 
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properties that are sub-optimal compared to mammalian gelatin (Haug et al., 2004, Schrieber 
and Gareis, 2007). 
Amphiphilic gelatin peptides obtained by acid hydrolysis of cold water fish gelatin were 
chosen as model drugs in this study. Fish gelatins from cold water species, such as cod and 
pollock, have a different amino acid composition compared to gelatins from mammalian 
sources and warm water fish species, as illustrated by Table 1.1 (Haug and Draget, 2009).   
Table 1.1: The composition of amino acids in collagen, type A and type B gelatins from 
bovine sources and in fish gelatins from both cold water and warm water species, given as 
number of amino acid residues per 1000 residues (Haug and Draget, 2009). 
 
 
 
 
 
 
 
 
 
 
The content of the imino acids Pro and Hyp are responsible for the differing physical 
properties between mammalian gelatins and cold water fish gelatins (Table 1.1). The low 
gelling modulus and low gelling and melting temperatures of cold water fish gelatin is a result 
of a lower content of Pro and Hyp compared to mammalian gelatin (Haug et al., 2004). The 
imino acids Pro and Hyp have aliphatic side chains with characteristic cyclic structures. The 
imino group that participates in peptide linkage is held in a rigid conformation that reduces 
the structural flexibility in regions of proteins and peptides containing Pro and Hyp (Nelson et 
al., 2008). The lower content of Pro and Hyp is therefore likely to give cold water fish gelatin 
a less rigid and more flexible chain conformation compared to mammalian gelatins with 
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higher imino acid content. Cold water fish gelatin has an isoelectric point (IEP) around 8-9.5, 
and thus a weak net positive charge at physiological pH (Gudmundsson, 2002). 
Cold water fish gelatins were considered a good choice as model drugs based on that gelatin 
is derived from collagen, which is a naturally occurring protein in skin.  In addition, cold 
water fish gelatins were chosen due to the possibly reduced chain rigidity in solution 
compared to mammalian gelatins. These structural features were believed to make fish gelatin 
applicable as vectors for transportation into the skin layers, and thus as model drugs in the 
transdermal diffusion experiments.      
1.5.2.  Alginate – a polyanionic model drug 
The alginate polymer have been used as device in human health applications, including 
excipients in drug delivery, immobilization of cells for possible use in human transplantation 
and cell therapy, drug delivery and wound dressings (Ertesvåg and Valla, 1998, Dettmar et al., 
2011, Draget and Taylor, 2011). Alginate is a linear polysaccharide primarily found in marine 
brown algae, where it constitute close to 40 % of the dry weight of the seaweed and function 
as a structural substance providing strength and flexibility to the tissue of the algae. In 
addition, soil bacteria, such as Azotobacter vinelandii, and a selection of Pseudomonas 
species, produce alginate for capsular protection and surface adhesion.  
The alginate molecule is a copolymer with a varying composition and sequence of (1→4)-
linked β-D-mannuronic acid (M) and α-L-guluronic acid (G) monomers (Figure 1.5a) (Draget 
et al., 2006, Smidsrød and Moe, 2008). The extended and stiff structure of alginate is a result 
of rotational hindrance caused by diaxial bonds in G-blocks (Draget et al., 2005, Draget and 
Taylor, 2011).  
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Figure 1.5: The structural characteristics of alginate. a) The two monomers β-D-mannuronic 
acid (M) and α-L-guluronic acid (G), b) the alginate chain presented in chair conformation 
and c) an alginate chain represented by the symbols of the monomers illustrating the block 
sequence (Draget et al., 2006).    
It is common to describe alginate as a block copolymer that contain M-blocks, G-blocks, and 
MG-blocks, where the former two are homopolymeric regions of M and G, respectively, and 
the third represents an alternating sequence of both monomers (Figure 1.5b and c). Both the 
fraction of M and G residues (FM and FG) and the length of the block sequences can vary 
greatly in an alginate molecule, ranging from a fully homopolymeric β-D-mannuronat 
polymer (FM = 1) to a polymer with a α-L-guluronate content of >70% (FG = 0.7). This 
variation in chemistry are reflected by alginates with various physical properties (Draget et 
al., 2006, Smidsrød and Moe, 2008).  
The pKa values of the carboxylic groups of M and G monomers are 3.38 and 3.65, 
respectively (Draget et al., 2006). This means that alginate is negatively charged at 
physiological pH and characterized as a polyelectrolyte (Smidsrød and Moe, 2008). The 
polyelectrolyte nature at pH > pKa make it possible for alginate to interact electrostatically 
with other charged polymers in a mixed system, resulting in phase transitions and altered 
rheological behavior (Draget et al., 2006). Recently, low molecular weight G-blocks have 
been found to enhance mucosal drug delivery. Interactions between mucin (negatively 
charged glycosylated proteins) and other macromolecules lead to increased mechanical 
properties in the mucus barrier. However, charged G-block oligoelectrolytes, which are too 
small to create intermolecular cross-links, can eliminate these types of interactions through 
electrostatic competitive inhibition. This elimination of interactions modifies the mucin 
network to such an extent that the structure opens up and drug bioavailability increases due to 
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increased mucosal uptake (Draget and Taylor, 2011). The negatively charged glycoproteins 
that constitute the mucin fibres in mucus can be compared to the components of the 
extracellular matrix throughout the human body (Alberts et al., 2002, Cone, 2009). G-blocks 
may therefore lead to the same alterations in the extracellular matrix as in the mucin network, 
and may thus enhance the delivery of drugs through transdermal administration. In addition, 
alginates of high G content are known to be non-immunogenic, while the opposite is true for a 
high content of M (Otterlei et al., 1991). For these reasons G-blocks were chosen as an 
appropriate model drug in transdermal diffusion experiments, giving rise to test molecules 
that possibly would behave very different in combination with skin compared to the cold 
water fish gelatins also used as model drugs.  
1.6. Fluorescence  
 
The process resulting in fluorescence occurs in certain molecules called fluorophores or 
fluorescent dyes, and comprises three stages: excitation, the lifetime of the exited state and 
emission (Haugland et al., 2005). This three-stage process is illustrated in Figure 1.6. 
(Haugland et al., 2005). 
 
Figure 1.6: Figure 1.7: Jablonski diagram, an electronic-state diagram, which illustrates the 
three processes excitation (1), the exited-state lifetime (2) and emission (3), which result in 
fluorescence (Haugland et al., 2005) 
In the first stage of the process leading to fluorescence, an external source of light provides a 
photon of energy, hυEX, that is absorbed by a fluorophore causing it to shift from its ground 
state (S0) to an exited state (S1 (Haugland et al., 2005).  Stage two of the process is the 
exited-state’s lifetime; a short period of time that equals the time an excited molecule remains 
in the excited state. This lifetime is also called the fluorescent lifetime and is usually in the 
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range of nanoseconds (10
-9
 s) to picoseconds (10
-12
 s)(Albani, 2007). During the excited-state 
lifetime the fluorophore undergoes the phenomenon of internal conversion, where a loss in 
energy to the environment results in the return of the excited fluorophore to its lowest or 
relaxed excited state (S1), which is the origin of fluorescence emission. From this state the 
fluorophore can return to its ground state (S0), through different competitive processes, 
including fluorescence emission, such as loss of energy as heat, release of energy to nearby 
molecules by collisional quenching or fluorescence resonance energy transfer (FRET), and 
intersystem crossing (Haugland et al., 2005, Albani, 2007). Fluorescence emission is the third 
and last stage, and when a photon of energy, hυEM, is emitted, the fluorophore returns to its 
ground state. Because of the energy loss during the exited-state lifetime the emitted photon, 
hυEM, have a lower energy level resulting in a longer wavelength compared to the excited 
photon, hυEX. The difference in wavelength between the excited and the emitted photon, hυEX 
- hυEM,  is called the Stokes shift (Haugland et al., 2005). 
The three-stage process of fluorescence is cyclical, meaning that one fluorophore can be 
excited and detected repeatedly. As long as the fluorophore avoids irreversible damage in the 
excited state, it can give rise to thousands of photons, a property essential for the high 
sensitivity provided by fluorescence detection techniques. Molecules consisting of multiple 
atoms in solution replace the single electronic transitions hυEX and hυEM with two  broad 
energy spectra, namely a fluorescence excitation spectrum and a fluorescence emission 
spectrum. For a single fluorophore the excitation spectrum is, almost without exception, 
identical to the absorption spectrum, and at the excitation wavelength the intensity of 
emission is proportional to the amplitude of excitation in the fluorescence excitation spectrum  
(Haugland et al., 2005). 
In all applications where fluorescent probes function as detection tools, such as in this study, 
the detection sensitivity can be affected by background signals. Interfering background 
signals can be a result of reagent background, where the signals are caused by unbound 
probes or probes bound nonspecific, or they can arise from endogenous sample constituents, a 
phenomena called autofluorescence (Haugland et al., 2005). The impact of autofluorescence 
can be studied by using longer wavelengths, as autofluorescence generally decreases when 
imaging at wavelengths greater than 550 nm (Zeiss et al., 2012). In human tissue 
autofluorescence is caused by endogenous fluorophores, and in human skin the known 
fluorophores are collagen, elastin, NADH, tryptophan, flavins and porphyrins. All of these 
fluorophores have certain excitation and emission wavelengths. Collagen-linked fluorescence 
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has excitation and emission bands in the region 330-500 nm, and has received increased 
interest due to its role in skin changes during aging and photoaging. Fluorescence from elastin 
is less studied due to its relatively weak signals, which is highly overlapped by the emission 
of other fluorophores (Na et al., 2001). When studying transdermal diffusion of fluorescently 
labeled molecules the contribution of autofluorescence should be taken into account. 
Autofluorescence corrections are of particular relevance when comparing transdermal 
diffusion in human skin from different donors or in skin retrieved from different body sites of 
a donor. 
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2. Materials and methods 
2.1. Materials 
2.1.1.  Fish gelatin - precursor for the fish gelatin peptides 
The cold water fish gelatin used as a model drug in skin diffusion experiments was provided 
by Norland Products Inc., USA (FG6, Batch 8004). It is a type A fish gelatin with a high 
molecular weight distribution (HMWD), produced from the skins of cod, haddock and 
pollock. 
2.1.2. Alginate - precursor for the G-blocks  
High guluronic acid Na-alginate (degraded alginate) was provided by FMC BioPolymer AS, 
Norway (Batch 907-255-01).  
2.1.3. Alexa Fluor® dyes 
The spectral properties of the three fluorophores applied in the fluorescence labeling of the 
fish gelatin peptides and G-block samples, are given in Table 2.1. All the dyes were 
purchased from Invitrogen, Norway.  
 
The Alexa 488/532 carboxylic acid, succinimidyl ester (CASE) fluorophores bind to primary 
amines in proteins, peptides and amine-modified nucleic acids via a Shiff base reaction and 
results in an amine bond that exhibit the stability of a peptide bond. The Alexa Fluor
®
 488 
hydrazide, sodium salt (HSS) fluorophore binds to the reducing end of polysaccharides 
through an aldehyde linkage (Invitrogen, 2010). 
 
Table 2.1: An overview of the spectral properties of the Alexa Fluor
®
 dyes, which include  
molecular weight (Mw), absorption/excitation maxima (λmax), emission maxima (λemission) and 
extinction coefficient (ε) (Invitrogen, 2010). 
Fluorescent dye MW [g/mol] λmax [nm] λemission [nm] ε [cm
-1
M
-1
] 
Alexa Fluor
®
 488 carboxylic 
acid, succinimidyl ester 
643,41 494 517 73000 
Alexa Fluor
®
 532 carboxylic 
acid, succinimidyl ester 
723,77 530 554 81000 
Alexa Fluor
®
 488 hydrazide, 
sodium salt 
570,48 493 517 73000 
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2.1.4. NaHCO3 - buffer 
Sodium bicarbonate (NaHCO3, 8.4 g) was dissolved in MQ-water and adjusted to pH 8.3 and 
500mL. The solution was applied in the conjugation of fish gelatin peptides to the Alexa 
Fluor
®
 dyes. 
2.1.5. DMSO 
Dimethyl sulfoxide (DMSO) is an aprotic solvent that was used both as solvent and as a 
chemically enhancing vehicle in the transdermal diffusion experiments (Sigma-Aldrich, 
France). 
2.1.6. PEG200 
A polyethylene glycol with an average degree of polymerization of 200 (PEG200) was used 
as a chemically enhancing vehicle in transdermal diffusion experiments (Batch 81150, Sigma-
Aldrich, Germany). 
2.1.7. PBS-buffer 
The phosphate buffered saline (PBS) was prepared by dissolving NaCl (8.0 g, MW = 58.44 
g/mol), Na2HPO4 ∙ 2H2O (1.44 g, MW = 177.99 g/mol ), KCl (0.2 g, MW = 74.55 ) and 
KH2PO4 (0.2 g, MW = 136.09 g/mol) in MQ water. The pH of the buffer was adjusted to 7.4, 
and the volume to 1000mL. This buffer constituted the receptor phase in the transdermal 
diffusion experiments. 
2.1.8. TissueTek®, O.C.TTM 
TissueTek
®
 is a tissue glue, which is a formulation of water-soluble glycols and resins that 
provide a convenient specimen matrix for cryostat sectioning at temperatures of -10°C and 
below (Sakura, Netherland). This material was used to attach skin biopsies on cork for 
transportation, and on a specimen disc to enable cryo sectioning. 
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2.2. Methods 
2.2.1. Preparation of fish gelatin peptide samples 
 
Fish gelatin (FG) peptides were prepared for two purposes; a general experiment to examine 
the kinetics of fish gelatin degradation to obtain FG peptides, and for preparation of FG 
peptides for further use in transdermal diffusion experiments. 
2.2.1.1. Degradation by acid hydrolysis - kinetics 
Fish gelatin (0.75 g) was dissolved in hydrochloric acid (HCl; 0.2 M, 5 mL). To obtain 
complete dissolution the fish gelatin was added into the liquid under stirring conditions at 
room temperature. This procedure was repeated for eleven different samples. The degradation 
was performed at 90°C, and sampling was performed after 1, 2, 4, 6, 8, 12, 16, 18, 20, 24 and 
36 hours, yielding eleven samples with different degradation time (Figure 2.1). Each sample 
was cooled to room temperature and adjusted to pH 6-7 with sodium hydroxide (NaOH; 1 M) 
to stop further degradation. Salt and small FG peptides were removed from the samples by 
dialysis (MWCO 100-500 Da) against MQ-water (8 L) at 4 °C. The MQ-water was changed 
every four hours during the day until the conductivity of the dialysis water was below 10 µS 
(µS), and as close as possible to 5 µS. All the degraded samples of fish gelatin were 
lyophilized and stored at - 40°C.  
Figure 2.1: Degradation of fish gelatin at 90°C, where each sample has different degradation 
time, providing in total eleven samples. An initial sample of fish gelatin is also represented in 
the scheme to illustrate a total of 12 samples in studying the kinetics of fish gelatin 
degradation by acid hydrolysis. 
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2.2.1.2. Degradation by acid hydrolysis  
Fish gelatin (5 g) was dissolved in HCl (0.2 M, 33.3 mL). The degradation was performed at 
90°C, and sampling was performed after 4, 12, 24 hours, yielding three samples with different 
degradation time (Figure 2.2). The degradation procedure was identical to the one performed 
during the kinetics experiment, including the purification by dialysis and the following 
lyophilization.  
Figure 2.2: Degradation of fish gelatin at 90°C, where each sample has different degradation 
time, yielding in total three samples. 
2.2.1.3. Conjugation of fish gelatin to Alexa Fluor® CASE dyes 
Fish gelatin peptides (100-500 mg) were dissolved in MQ-water (1-2.5 mL), and mixed with 
NaHCO3 buffer (0,2 M, pH 8,3) in the ratio 1:1. To ensure uncharged amino groups in the fish 
gelatin samples, enabling reaction with the carboxylic groups found in the fluorophores, the 
pH of the solutions should be >7.  
The Alexa 488/532 CASE (1 mg) (Table 2.1) was first dissolved in 99% DMSO (0.2 mL) and 
mixed using a vortex mixer. Further the fluorescent dye (50 µL) was added drop wise to the 
respective peptide sample, and the mixture was covered by aluminum foil and incubated for 
nineteen hours under stirring conditions at room temperature. Aluminum foil was used to 
minimize light exposure of the fluorescent dyes. 
Excess fluorescent dye in the protein-dye mixtures was removed by dialysis (MWCO 1000 
Da) against MQ-water (8 L). The MQ-water was changed every four hours during the day 
until the fluorescence intensity of the dialysis water, measured by a Perkin Elmer LS 50B 
fluorescence spectrometer (PerkinElmer, Inc., Massachusetts, USA), was below 2 (I<2). 
Dialysis was followed by lyophilization, without exposure to light, and the lyophilized 
samples were stored at -40°C. 
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The flow diagrams below (Figure 2.3) give an overview of the different fish gelatin peptides 
generated by acid hydrolysis, each named FG# where # represents the degradation time in 
hours, and of the samples selected for conjugation to Alexa Fluor
®
 CASE dyes. 
 
 
 
a) b) 
Figure 2.3: Flow diagrams illustrating the initial source of fish gelatin, fish gelatin peptides 
with different degradation times, and the samples conjugated to Alexa Fluor
®
 dyes. In a) the 
amount of initial material was 0.75 g, and in b) the initial amount was 5 g.   
Initially, the fish gelatin samples FG4, FG12 and FG24, prepared for further use in 
transdermal diffusion experiments, were the only samples to be fluorescently labeled with 
Alexa Fluor
®
 488/532 CASE. However, as the experiments proceeded it was discovered that 
the difference in molecular weight among the three samples were much smaller than expected 
(Table 3.3). Therefore, FG2, with a higher estimated molecular weight was conjugated to 
Alexa Fluor
®
 488 CASE. 
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2.2.2. Preparation of G-block samples 
G-blocks with two different molecular weight distributions were used as model drugs in 
transdermal diffusion experiments. The two different G-block samples were prepared from 
acid precipitation of high guluronic acid NA-alginate, performed in two separate master’s 
thesis, by Karianne Birkestøl Eiken (Eiken, 2011) (G-DP22) and Tone Aspevik (Aspevik, 
2010) (G-DP18), respectively. Conjugation of G-DP18 and G-DP22 to Alexa Fluor
®
 488 HSS 
was performed by Karianne Birkestøl Eiken (Eiken, 2011). The number average degree of 
polymerization (DPn) of the two samples was determined by 
1
H-NMR, as described in section 
2.2.3.3.       
2.2.3. Determination of molecular weight and molecular weight distribution 
Polymers consist of varying amounts of monomers and to determine their molecular weights 
it is necessary to use defined equations for calculation of weight averages. The number 
average molecular weight (Mn) and the weight average molecular weight (Mw) are defined in 
Equations (2.1) and (2.2) (Smidsrød and Moe, 2008). 
 
i i ii i
n
i i ii i
N M c
M = =
N (c M )
       (2.1) 
2
i i i ii i
w
i i ii i
N M c M
M = =
N M c
       (2.2)  
     
In the equations, ci is the concentration of molecules, and Ni is the number of molecules with 
molecular weight Mi. Each molecule influences the two different averages Mn and Mw in 
proportion to their number or their weight, respectively. In the number average molecular 
weight all molecules will have the same influence on the average value. In the weight average 
molecular weight the large molecules will contribute to an increase in the average value due 
to the square root of the molecular weight in Equation (2.2) (Smidsrød and Moe, 2008). 
Polymer solutions are either monodisperse or polydisperse. In a monodisperse solution all 
molecules have the same weight, and per definition Mn equals Mw. The situation is somewhat 
different for a polydisperse solution, where the molecules are of varying molecular weights, 
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and Mn has a lower value compared to Mw. The ratio between Mw and Mn is the definition of 
the polydispersity index (p.i) used to roughly measure the polydispersity in a sample 
(Smidsrød and Moe, 2008).  
Mn and Mw of the FG samples were determined by both size-exclusion chromatography 
coupled to multi-angle laser light scattering (SEC-MALLS) and matrix-assisted laser 
desorption/ionization – time-of-flight (MALDI-TOF). Mn of the G-block oligomer samples 
were determined from data obtained from 
1
H-NMR. 
2.2.3.1. SEC-MALLS  
Size-exclusion chromatography coupled to multi-angle light scattering (SEC-MALLS) is a 
widespread method for the absolute determination of the molecular weight averages and 
molecular weight distributions. In SEC-MALLS two on-line detectors are used: a 
concentration sensitive detector (refractive index (RI) or UV detector) and a light scattering 
detector, which is able to monitor up to 18 laser angles simultaneously (Christensen, 2010b). 
Mn and Mw of the FG samples were determined from SEC-MALLS. The 15 different gelatin 
samples were dissolved in MQ-water. The initial fish gelatin sample, and samples degraded 
for 1, 2 and 4 hours were dissolved to 2 mg/mL, samples degraded for 6, 8, 12 and 16 hours 
were dissolved to 6 mg/mL, and samples degraded for 18, 20, 24 and 36 hours were dissolved 
to 10 mg/mL. All the dissolved samples were filtered (pore size 0.2 µm, low protein binding 
membrane; Acrodisc
®
 Syringe Filters with GHP membrane, PALL Corp., USA). The eluting 
buffer consisted of Na2SO4 (0.1 M) and Na2EDTA (0.02 M) and was adjusted to pH 9. The 
experimental procedure was described by Eysturskarð et al. (2009), and the analysis was 
performed by Ann-Sissel Teialeret Ulset, Staff Engineer at the Department of biotechnology, 
NTNU. 
2.2.3.2. MALDI-TOF  
In mass spectrometry the mass to charge ratio (m/z) of ions are measured and allows for the 
molecular weight to be determined. In matrix-assisted laser desorption/ionization – time-of-
flight (MALDI-TOF) proteins or peptides are crystallized in a matrix that absorbs at the 
wavelengths of a high energy pulsed laser. When the matrix is irradiated by this laser the 
energy is transferred to the molecules to be analyzed. The resulting ions, with unique size and 
charge, are accelerated by a high voltage electric field through a vacuum tube and towards a 
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detector. The TOF-detector measures the time it takes for the ion to fly to the detector, and 
this time-of-flight is proportional to the square root of m/z (Clark, 2005).  
The fish gelatin peptides FG1-FG36 (1 mg) were dissolved in MQ-water (1 mL). 2µL of each 
sample solution was mixed with 2µL of a sinapinic acid (SA) matrix, dissolved in acetonitrile 
(ACN) and trifluoroacetic acid (0.1% TFA) (ratio 3:1). 1 µL of the sample-matrix mix was 
applied onto a MALDI target plate (AnchorChip
TM
 Technology) and was allowed to dry. A 
N2 nitrogen laser with 337 nm wavelength (pulse energy of 100μJ) was utilized to irradiate 
the matrix and the analyses were performed in a linear positive mode. The experimental 
procedure was described by the autoflex
®
 Operator Manual (Bruker Daltonik GmbH, 2001, 
Germany) (given on the enclosed cd) and by Webster and Oxley (2005), and was performed 
by Kåre Andre Kristiansen, Senior Engineer at the Department of biotechnology, NTNU.   
2.2.3.3. 1H-NMR  
1
H-Nuclear Magnetic Resonance Spectroscopy (
1
H-NMR) is a method utilizing a samples 
ability to absorb electromagnetic energy in a magnetic field in order to determine its structural 
and chemical composition. The average degree of polymerization (DPn) and the fractions of 
M and G monomers (FM and FG) of the G-block samples, used as model drugs in the 
transdermal diffusion experiments, were determined by 
1
H-NMR prior to this study. The 
1
H-
NMR analysis was performed according to Holtan (2006), with the exception of acid 
hydrolysis, and was carried out by Wenche Iren Strand, Staff Engineer at the Department of 
biotechnology, NTNU. 
1
H-NMR spectra were recorded on a Bruker Avance DPX 300 and the 
spectra peaks were determined according to Grasdalen (1983).  
2.2.4. Determination of the degree of labeling  
The degree of labeling (DOL) (Equation 2.3) specifies the number of moles of Alexa Fluor
®
 
dyes conjugated to one mole of peptide or oligomer. In order to determine DOL, fluorescently 
labeled FG and G-block samples were diluted in MQ-water to a concentration of 0.1 mg/mL, 
and the absorbance was measured with a Lambda 25 UV/VIS Spectrometer (Perkin Elmer 
Inc., Massachusetts, USA) at the absorbance maximum (λmax) of the respective dyes (Table 
2.1). 
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max w
protein dye
A M
DOL
c


 
         (2.3) 
In the equation, which originally is defined for labeling of proteins, Amax is the absorbance of 
the protein-dye complex measured at the λmax of the dye and Mw is the molecular weight of 
the protein (g/mol). εdye is the extinction coefficient of the dye at its absorbance maximum 
(cm
-1
 · M
-1
) (Table 2.1). The concentration of dye in the protein-dye complex can be 
considered negligible giving a protein concentration, cprotein, equal to the cprotein-dye complex of 0.1 
mg/mL.     
2.2.5. Transdermal diffusion experiments 
The full-scale skins used in the transdermal diffusion experiments were donated from healthy 
female adults who had undergone abdominal plastic surgery at Clinic Stokkan in Trondheim. 
This study was approved by the local ethics committee, and all skin donors signed an 
informed consent. In total, skin samples from 11 donors were used in the experiments, and 
each donor was labeled alphabetically from A to K. The skin was transported to the laboratory 
at NTNU Gløshaugen immediately after pick up at Clinic Stokkan, to prepare it for use in 
transdermal diffusion experiments. The experiments were performed in a laboratory approved 
for experiments utilizing human skins and cells, classified as biohazard level 2, and entry was 
only allowed for students/staff vaccinated for hepatitis A/B. The preparation procedure started 
with removal of the subcutaneous fat applying surgical scissors. Skin thickness measurements 
were performed by measuring the thickness at 10 different locations on the skin samples from 
each donor with a digital slide gauge (micromaster
®
, capa µ system, Swiss Instruments Ltd, 
Ontario, Canada). All skin samples were investigated for areas with a lot of hair, stretch 
marks, tattoos and perforations that potentially could affect the diffusion of the test molecules 
into the skin.        
2.2.5.1. Pretreatment of the skin 
The skin samples from all the different donors were either untreated, or pretreated with micro-
needles or laser. The surface and structure of untreated skin was not altered prior to applying 
the test molecules. A solid micro-needle device, Dermaroller
®
 MC915 (1.5 mm, Dermaroller 
LLC, California, USA) (Figure 2.4a), was used to porate the stratum corneum, creating small 
channels to enhance the diffusion of macromolecules across the outermost barrier of the skin. 
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Pretreatment with micro-needles was performed by rolling the Dermaroller
®
 MC915 over the 
skin surface once with a constant pressure (Figure 2.4b). 
Three different laser treatments were applied (Table 2.2). The laser pretreatment was 
performed with the ablative CO2 fractional laser eCO2
TM
 (Lutronic Inc., Seoul, Korea) by Dr. 
MD Ole Martin Rørdam (Figure 2.4c). However, the laser pretreatment applied in skin 
diffusion kinetics experiments was performed with a fractional erbium:YAG laser (Sciton 
Inc., California, USA), mimicking laser treatment 1 (Table 2.2) . For practical reasons the 
skins were treated with laser before removal of the subcutaneous fat tissue. Each of the three 
different laser treatments resulted in spherical points consisting of multiple laser spots with 
identical diameters and depths (Figure 2.4d). The spot density varied between the three 
different laser treatments, and the depth of the laser spots increased with increasing pulse 
energy.  All three laser treatments were first applied in a pilot study to investigate the effect of 
laser radiation regarding both transdermal diffusion of model drugs and skin damage, and 
laser treatment 1 (L1) was chosen for further use in transdermal diffusion experiments. 
Table 2.2: Overview of the three different laser treatments performed on human skin, 
including the pulse energy, laser strength and density of spots. 
Laser treatment Pulse energy (mJ) 
 
Laser power (W) Density 
(Spots/cm
2
) 
L1 14 30 400 
L2 30 30 300 
L3 40 30 600 
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a) 
 
 
b) 
 
 
 
 
c) 
 
d) 
Figure 2.4: a) The Dermaroller
®
 MC915 used to porate the stratum corneum to enhance the 
diffusion of macromolecules through skin, b) a tissue sample pretreated with Dermaroller
®
 
MC915 illustrating the poration of the skin surface, c) the CO2 fractional laser eCO2
TM
 used 
for laser treatments (Lutronic, Seoul, Korea), d) a tissue sample pretreated with laser 
treatment 3 (picture taken after the diffusion experiment).  
2.2.5.2. The general experimental design of transdermal diffusion 
experiments 
The general experimental design was identical for all the different transdermal diffusion 
experiments, regardless of pretreatment of the skin and the test samples applied. After the 
initial removal of subcutaneous fat and redundant liquids, the skin was placed on a plate of 
polystyrene covered with aluminum foil. Further, the skin was cut into smaller tissue samples 
(≈ 3x3 cm) that fitted onto a Franz-type diffusion cell (PermeGear, Inc, Pennsylvania, USA), 
used to investigate transdermal diffusion. The diffusion cell consisted of an application 
chamber and a receptor chamber, both with a diameter of 20 mm. The receptor chamber (15 
mL) was filled with PBS (pH 7.4), which constituted the receptor phase. Each tissue sample 
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was mounted between the application and the receptor chamber by a screw clamp, with the 
epidermal side facing the application chamber and the dermal side facing the receptor 
chamber, (Figure 2.5). The receptor phase volume was adjusted through the sampling port, 
and the test samples were deposited on the epidermal side of the tissue sample in the 
application chamber (4 (w/v)%, 30 µL) with an automatic pipette. For pretreated skins it was 
important that the treated area was accessible for test sample deposition in the application 
chamber. Both the application chamber and the sampling port were closed by parafilm, and in 
addition the application chamber was covered with aluminum foil to prevent evaporation and 
exposure to light. The Franz cells were placed in small water baths, where the water covered 
approximately half of the receptor chamber, and the units were incubated in darkness at 30˚C 
for 22 hours. To study the diffusion kinetics the incubation time was varied, depending on the 
pretreatment of the skin and the fluorescently labeled model drugs used. In the pilot study, 
performed to investigate the effect of laser treatments, the Franz cells were incubated for 48 
hours due to practical reasons.     
 
 
a) b) 
Figure 2.5: a) Schematic representation of a Franz-type diffusion cell, where a skin sample is 
mounted between the application and the receptor chamber (Adapted from (Moser et al., 
2001)), b) a real life Franz-cell unit with a tissue sample from human skin mounted between 
the application and the receptor chamber by a screw clamp.   
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2.2.5.3. Measure of fluorescence intensity in the receptor phase (IRP)  
After incubation the skin samples were carefully removed from the Franz cells, and the 
receptor phase transferred to a test tube. The fluorescence intensities in each individual 
receptor phase were measured using a Perkin Elmer LS 50B fluorescence spectrometer 
(PerkinElmer, Inc., Massachusetts, USA). For receptor phases collected from experiments 
involving molecules conjugated to Alexa Fluor
®
 488 CASE or HSS the fluorescence intensity 
was measured at the excitation/emission wavelengths 495/519 nm. For receptor phases 
collected from experiments involving test samples conjugated to Alexa Fluor
® 
532 CASE the 
same measurements were made at wavelengths 514/532 nm.  
The maximum possible fluorescence intensity in the receptor phase was determined, by 
adding test samples (10 µL) directly into PBS (5 mL, pH 7.4). 
2.2.5.4. Biopsy punching 
The skin samples removed from the diffusion cells were attached to a polystyrene plate by the 
help of hypodermic needles. Excess test sample was removed from the skin surface by tissue 
paper, and a biopsy was collected for each tissue sample using a biopsy puncher with a 
diameter of 5mm. Between each biopsy punch the puncher was washed in 70% EtOH to avoid 
transfer of fluorescence from one biopsy to another. By using TissueTek
®
 O.C.T
TM
 (Sakura 
Finetek Europe B.V., Netherlands) every biopsy specimen was attached to a small, 
rectangular piece of cork followed by deep-freezing in liquid nitrogen. The frozen biopsies 
were completely covered by TissueTek
®
 O.C.T
TM
, deep-frozen, and stored in cryo tubes (1.8 
mL) at - 40˚C until cryo sectioning     
2.2.5.5. Cryo sectioning 
Cryo sectioning basically means sectioning under cold conditions, and all the biopsies were 
sectioned using a Leica CM 3050 S cryostat (Leica Microsystems, Wetzlar, Germany) (Figure 
2.6a). The cryo sectioning was performed at the Department of cancer research and molecular 
medicine at Gastrosenteret, St.Olavs Hospital, in Trondheim. In the cryostat the cryochamber 
temperature was set to -25˚C and the specimen temperature to -12˚C. Each biopsy was 
removed from the cork material and mounted with TissueTek
®
 O.C.T
TM
 on a specimen disc 
(Figure 2.6b). After deep-freezing in the cryochamber the biopsies were prepared for 
sectioning (Figure 2.6c), and the sectioning thickness was set to 20 µm. During cryo 
sectioning thin slices of the biopsies were transferred to SuperFrost® microscope slides 
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(Menzel-Glaser GmbH, ThermoFischerScientific Inc., USA) (Figure 2.6d). The microscope 
slides were stored in light-proof boxes under dry conditions at room temperature.  
 
 
 
a) b) 
 
 
 
c) 
 
d) 
Figure 2.6: a) The Leica CM 3050 S Cryostat (Leica Microsystems, Germany), b) a skin 
biopsy mounted with TissueTek
®
 O.C.T
TM
 on a specimen disc, c) deep-freezing of biopsies in 
the cryochamber, prepared for cryo sectioning, d) slices (20 µm) of skin biopsy on a 
microscopic slide.  
2.2.6. Overview of the performed diffusion experiments 
Table 2.3 gives an overview of the transdermal diffusion experiments performed to study the 
diffusion of fish gelatin peptides and G-block oligomers into human skin. In all the 
transdermal experiments, with exception of the pilot study and the skin diffusion kinetics 
experiments, diffusion of pure Alexa Fluor
®
 488 CASE/HSS was also studied, to provide 
“positive” control tissues giving rise to fluorescence. “Negative” control tissues were obtained 
by applying only the vehicles on the skin. These control experiments were performed 
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simultaneously with the peptide and oligomer samples to be studied, and thus, the same 
vehicles and skin pre-treatments were utilized.       
Table 2.3: Overview over the performed transdermal diffusion experiments, including skin 
donor, the sample and vehicle applied, and skin pretreatment.    
Donor Sample Vehicle(s) Skin 
pretreatment(s) 
Comment 
A FG24 488 CASE 
FG24 532 CASE 
60% DMSO 
 
L1, L2 and L3 Pilot study – effect of laser 
pretreatment 
B FG 24 488 CASE 60% DMSO L1 Transdermal diffusion 
experiment 
E FG24 488 CASE 
Alexa 488 CASE 
60% DMSO Micro-needles Skin diffusion kinetics 
experiment 
F FG24 488 CASE 
Alexa 488 CASE 
60% DMSO Micro-needles Skin diffusion kinetics 
experiment 
G G-DP18 488 HSS 
G-DP22 488 HSS 
10% PEG200 Untreated 
Micro-needles 
Transdermal diffusion 
experiment 
H FG24 488 CASE 60% DMSO 
10% PEG200 
Untreated 
Micro-needles 
Transdermal diffusion 
experiment 
I G-DP18 488 HSS 
G-DP22 488 HSS 
60% DMSO Untreated 
Micro-needles 
Transdermal diffusion 
experiments 
J FG24 488 CASE 
Alexa 488 CASE 
60% DMSO L1 
(Sciton laser) 
Skin diffusion kinetics 
experiment 
K FG2 488 CASE 
FG24 488 CASE*
 
60% DMSO 
10%PEG200 
Untreated 
Micro-needles 
L1 
Transdermal diffusion 
experiment 
*The FG24 488 sample was applied in a 10% DMSO vehicle on skin from donor K after pretreatment with L1 
2.2.7. Imaging of the skin tissues; confocal laser scanning microscopy 
In confocal laser scanning microscopy (CLSM) laser light of defined wavelengths are used as 
light source and is directed as a laser spot towards the sample. An illustration of a confocal 
optical system is given in Figure 2.7. When the laser light reaches the sample the 
fluorescently labeled molecules are excited and the emitted light is collected by the objective 
lens. This brings the light towards a photomultiplier tube (PMT) detector. A pinhole is placed 
in front of the detector, where only light from the focal plane is allowed to pass. Out-of-focus 
light will spread over a larger area at the pinhole, allowing only a small fraction to pass 
through it and thereby out-of-focus light is excluded from contributing in creating the final 
image. This feature of LSCM enables capturing of clear images of thick samples, and imaging 
of individual planes of thick objects, called optical sectioning (Cox, 2007).   
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Figure 2.7: Illustration of a confocal optical system, where the laser light is directed towards 
confocal plane of the sample. Solid lines indicate in-focus light, dotted lines indicate out-of-
focus light.  
The microscope slides were studied using a Leica TCS SP5 confocal laser scanning 
microscope coupled to the Leica LAS AF software (Leica Microsystems, Wetzlar, Germany). 
Cover glasses (Menzel-Glaser GmbH, ThermoFischerScientific Inc., USA) were placed over 
the tissues on the microscope slides right before imaging. Standardized settings were 
determined and applied during imaging of all the tissue samples to obtain comparable images. 
For the study of samples conjugated to Alexa Fluor
®
 488 CASE/HSS an argon laser was used, 
and the standardized settings are given in Table 2.4. The FG24 sample conjugated to Alexa 
Fluor
®
 532 CASE were studied by applying a combination of an argon and a DPSS 561 laser, 
and the standardized settings are given in Table 2.5.  
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Table 2.4: Standardized settings applied for imaging of skin tissue after transdermal diffusion 
of sample molecules conjugated to Alexa Fluor
®
 488 CASE/HSS by CLSM. 
Laser Argon (17%) 
Beam path setting 488 
PMTs  
(photo multiplier tubes) 
PMT 1 (system 1) 
Mode Leica/Alexa 488 
Gain 774.2 
Offset 0% 
PMT Trans (transmitted light channel) 
Mode Leica/BF Scan 
Gain 208.1 
Offset 0% 
Image resolution 1024x1024 pixels (1550x1550 microns) 
Scan speed 400 Hz 
Zoom factor 1 
Pinhole Airy 1  
Line average 4 
Frame average 1 
z-stack Wide 
Objective HC PLAPO CS 10x0.4  DRY 
 
Table 2.5: Standardized settings applied for imaging of skin tissue after transdermal diffusion 
of sample molecules conjugated to Alexa Fluor
®
 532 CASE by CLSM. 
Laser Argon (17%) and DPSS 561 
Beam path setting 488 and 561 
PMTs  
(photo multiplier tubes) 
PMT 2 (system 2) 
Mode Leica/Cy3 
Gain 774.2 
Offset 0% 
PMT Trans (transmitted light channel) 
Mode Leica/BF Scan 
Gain 206 
Offset -11% 
Image resolution 1024x1024 pixels (1550x1550 microns) 
Scan speed 400 Hz 
Zoom factor 1 
Pinhole Airy 1  
Line average 4 
Frame average 1 
z-stack Wide 
Objective HC PLAPO CS 10x0.4  DRY 
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The images captured by the CLSM were exported to the Java-based image processing 
program ImageJ 1.45 (ImageJ, U.S, Maryland, USA), where tissue fluorescence intensity 
measurements were performed. The intensity values were detected within a range of 0-255 
(where 0 (minimum) = black and 255 (maximum) = bright green/red). The mean fluorescence 
intensity in the tissue (Imean-tissue) was determined using the polygon selection tool in the 
ImageJ toolbar. Three intensity profiles were drawn in the longitudinal direction in the tissue, 
from the outer edge of SC to the deepest skin layers captured in the image. The average 
fluorescence intensities obtained from the three plot profiles resulted in intensity plots with 
fluorescence intensity as a function of tissue depth. 3D surface plots were made using an 
interactive 3D surface plot plugin, illustrating the distribution and intensity of fluorescence in 
the tissue.  
The mean autofluorescence intensity (Iauto) in the tissue was measured using the same polygon 
selection as for Imean-tissue in the control tissues. Imean-tissue could therefore be corrected for Iauto, 
to yield Imean-sample, according to Equation (2.4). 
 
mean-sample mean-tissue autoI = I ± SD - I ± SD      (2.4)   
 
Imean-sample : Fluorescence intensity in the tissue only due to transdermal diffusion of   
fluorescently labeled sample, given as Imean-sample ± SD 
 
Imean-tissue : Fluorescence intensity in the tissue due to both trandermal diffusion of 
fluorescently labeled sample and tissue autofluorescence, given as Imean-tissue ± 
SD 
 
Iauto : Tissue autofluorescence given as Imean-control ± SD 
 
Imean-control : Mean fluorescence intensity in the control tissue, given as Imean-control ± SD   
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All the fluorescence intensity values in Equation (2.4) are given as mean values ± SD. 
Because the measured Imean-tissue and Iauto values are not independent of each other the standard 
deviation from both measurements are added together, resulting in a higher SD for Imean-sample, 
as given in Equation (2.5) (Taylor, 1997).  
mean-sample mean-tissue auto tissue autoI = I - I ± (SD +SD )     (2.5)  
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3. Results and discussion 
3.1. Molecular weight determination  
The weight average molecular weight (Mw) and the number average molecular weight (Mn) of 
fish gelatin (FG) peptides were determined by both SEC-MALLS and MALDI-TOF analyses. 
An estimation of the mean molecular weights of the different FG peptides was performed by 
combining the results from the SEC-MALLS and MALDI-TOF analyses. The results from the 
1
H-NMR analyses were used to determine the number average molecular weight for the G-
block oligomers. 
3.1.1.  Molecular weight determination of fish gelatin by SEC-MALLS 
The results of the SEC-MALLS analyses for determination of Mn and Mw are given in Table 
3.1, and the raw data are given in Appendix A. The calculated mass (mcalc) is the amount of 
the injected fish gelatin molecules, detected by the RI-detector. The Mw and Mn were 
determined for the molecules comprising the mcalc, which is the fish gelatin molecules eluted 
from the SEC column prior to the buffer salt void. The difference between the injected mass 
of fish gelatin molecules (minjected) and mcalc provides information about the separation of the 
molecules. The lower mcalc compared to minjected (Table 3.1) indicated that not all molecules 
injected into the SEC-columns were eluted before the buffer salts. This may further indicate 
that small fish gelatin molecules were lost in the salt signal. The molecular weight distribution 
for a selection of the degraded fish gelatin samples are given in Figure 3.1. 
Table 3.1: Results from the SEC-MALLS analyses of fish gelatin samples. The calculated 
mass (mcalc) represents the mass of the injected fish gelatin molecules eluted before the salt 
signal, from which Mw and Mn were determined.   
Sample minjected 
(g) 
mcalc 
(g) 
Mw 
[g/mol] 
Mn 
[g/mol] 
Initial 2.00 ∙ 10
-4 1.12 ∙ 10-4 119700 117200 
FG1 2.00 ∙ 10
-4
 1.274 ∙ 10-4 14080 12570 
FG2 2.00 ∙ 10
-4
 1.09 ∙ 10-4 10000 9025 
FG4
 2.00 ∙ 10-4 1.005∙ 10-4 6452 6083 
FG6 6.00 ∙ 10
-4
 4.07 ∙ 10-4 4218 4078 
FG8 6.00 ∙ 10
-4
 3.90 ∙ 10-4 4134 3990 
FG12 6.00 ∙ 10
-4
 4.03 ∙ 10-4 3484 3391 
FG16 6.00 ∙ 10
-4
 4.35 ∙ 10-4 2764 2641 
FG18 1.00 ∙ 10
-3
 6.94 ∙ 10-4 2708 2537 
FG20 5.00 ∙ 10
-4
 4.80 ∙ 10-4 2947 2839 
FG24 1.00 ∙ 10
-3
 7.46 ∙ 10-4 2594 2409 
FG36t 1.00 ∙ 10
-3
 7.41 ∙ 10-4 2324 2248 
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The molecular weight averages determined by SEC-MALLS (Table 3.1) indicated a trend of 
decreasing molecular weight with increasing degradation time. During the first hour the 
degradation was more extensive, but as the degradation time increased, the rate of degradation 
seemed to decrease. This resulted in low molecular weight gelatin peptides with a wide 
molecular weight distribution indicating that the samples were polydisperse (Figure 3.1). 
 
Figure 3.1: The molecular weight distributions of FG peptides obtained from acid hydrolysis 
of the initial FG after 6, 12, 18, 24 and 36 hours of degradation.  
As mentioned above, the mcalc indicated that a proportion of each sample was excluded in the 
salt cut-off range of the MALLS integration, and therefore did not contribute in the molecular 
weight determination. Due to the columns applied in the analyses it was likely to believe that 
the low molecular weight peptides in the samples to a large extent were eluted in the salt void, 
and thus the high molecular weight fractions of the samples were overestimated. Because of 
this the molecular weight averages determined from SEC-MALLS were considered to 
represent a high molecular weight fraction of the FG samples (FHMW). The FHMW 
corresponded to the ratio between mcalc and minjected, as given in Equation (3.1). The remaining 
portions of the samples, assumed to be excluded in the salt void during separation, were 
consequently considered to constitute the low molecular weight fraction of the FG peptides 
(FLMW), and were calculated according to Equation (3.2).  
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LMW HMW
F =1-F          (3.2) 
 
The minjected for the FG peptides may have been misleading, as the water content of the 
gelatins was unknown. Presence of water in the FG peptides would be expected to contribute 
to a deviation from the actual weight of the FG peptide samples, prepared for dissolution in 
MQ-water and injection into the SEC column (subsection 2.2.3.1). The actual amount of FG 
peptides injected into the column was therefore believed to be somewhat smaller than the 
minjected obtained from the SEC-MALLS raw data. This may further have had an impact on the 
calculated ratio between mcalc and minjected (Equation 3.1). 
In MALLS there is a lower detection limit in the range of λ/20, meaning that for a laser 
wavelength of 658 nm, which was applied in the analyses, only peptide molecules with a RG > 
~30 nm (radius of gyration) can be considered. For molecules where RG is small compared to 
the laser wavelength, the laser light is unable to resolve the structure of the molecules, and it 
can be considered as point scattering rather than multi-angled light scattering (Christensen, 
2010a). From the SEC-MALLS results (Appendix A) none of the measured radius moments 
were above this limit and for many of the samples the radius were undetectable. A low RG 
represents a low degree of chain extension, and highly contracted FG molecules could 
therefore also contribute to give small low molecular FG peptides that are eluted with the salt. 
3.1.2. Molecular weight determination of fish gelatin by MALDI-TOF 
The results of the MALDI-TOF analyses for determination of molecular weight are given in 
Table 3.2. The mass spectra are given in Appendix B and the raw material on the enclosed cd. 
The initial FG sample was not included in the MALDI-TOF analyses due to its high 
molecular weight, and was only analyzed by SEC-MALLS. 
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Table 3.2: Mw and Mn determined by MALDI-TOF. The molecular weight averages are 
based on intensity.  
Sample Mw 
[g/mol] 
Mn 
[g/mol] 
FG1t 5506 3983 
FG2t 5131 4145 
FG4t 4618 3812 
FG6t 5246 3961 
FG8t 4584 3484 
FG12t 4488 3679 
FG16t 4525 3681 
FG18t 4427 3679 
FG20t 4716 3944 
FG24t 3951 2990 
FG36t 4683 3738 
 
The results from the MALDI-TOF analyses indicated no clear correlation between molecular 
weight and degradation time, instead all samples, regardless of degradation time, seemed to 
be in the same low molecular weight range. This is in accordance with the fact that high-mass 
ions are underestimated in cases of high polydispersity (PI >1.1) (Gross, 2011), which seems 
to be true in this case. The underestimation of the high molecular weight molecules, and thus 
overestimation of the low molecular weight molecules, was the opposite of what was found in 
the SEC-MALLS analyses. Therefore, the molecular weights given in Table 3.2 were 
considered to constitute the FLMW (Equation 3.2) of the FG peptide samples. 
3.1.3. Estimated weight average molecular weight (Mw) by combining the results 
from SEC-MALLS and MALDI-TOF 
The weight average molecular weight (Mw) was the molecular weight average of interest 
when performing molecular weight determination by SEC-MALLS and MALDI-TOF. This 
parameter is required in determining the degree of labeling, and is of experimental value with 
regards to the size-dependency of molecules diffusing into the skin. Because of the 
overestimation of the high molecular weight compounds in SEC-MALLS and the 
overestimation of low molecular weight compounds in MALDI-TOF, an estimated average 
weight of each FG sample was determined by combining the results from SEC-MALLS and 
MALDI-TOF. The average molecular weights were calculated in accordance with Equation 
(3.3) and the estimated average Mw of the 12 FG samples are given in Table 3.3. 
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   w HMW w (SEC-MALLS) LMW w (MALDI-TOF)M = F · M  + F · M     (3.3) 
 
Table 3.3: The estimated average Mw of the 12 FG samples after combining the results from 
the SEC-MALLS and MALDI-TOF analyses.   
Sample 
wM  
FG0 120000 
FG1 11000 
FG2 8000 
FG4 6000 
FG6 5000 
FG8 4000 
FG12 4000 
FG16 3000 
FG18 3000 
FG20 3000 
FG24 3000 
FG36 3000 
 
The results given in Table 3.3 show a correlation between duration of acid hydrolysis and 
average molecular weights, and longer time of acid hydrolysis gave FG peptides with lower 
average molecular weights, as expected.  After 16 hours all the unstable peptide linkages 
appeared to be broken, and the peptides degraded for 16-36 hours obtained the same 
molecular weight. Further depolymerization would therefore not be possible unless the 
experimental conditions were changed, such as acid concentration, type of acid and/or 
temperature. The weight average molecular weights determined from Equation (3.3) are not 
absolutely correct since the low and high molecular weight cut offs in the two applied test 
methods are not known. This means that both the high and low molecular weight fractions 
may include some of the same molecules. Still, the calculated molecular averages are assumed 
to provide DOL data, which are more correct than applying Mw from either the SEC-MALLS 
or MALDI-TOF analyses. The molecular weight values given in Table 3.3 are rounded to the 
nearest 1000, and are solely regarded as rough estimates due to the uncertainties related to 
each of the analyses and the combination of the results. 
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3.1.4. Molecular weight determination of G-block 
The Mn of G-DP18 and G-DP22 were determined from the results of the 
1
H-NMR analyses 
performed prior to this study. The analyses resulted in two 
1
H-NMR spectra, one for G-DP18 
and one for G-DP22, respectively. The spectra are given in Appendix C. The fractions of G- 
and M monomers, and the number average degree of polymerization (DPn) of the samples 
determined from the 
1
H-NMR spectra, are given in Table C.1 in Appendix C.  
The DPn of the two G-block samples were determined to be 18 and 22, respectively. The 
molecular weight of the Na-alginate monomers (guluronic and mannuronic acid) are 198.1 
g/mol. The Mn of G-DP18 and G-DP22 was calculated in accordance to Equation (3.4) and 
are given in Table 3.4.  
n n
M = 198.1 g/mol · DP          (3.4) 
 
Table 3.4: The n of G-DP18 and G-DP22.  
Sample n (g/mol) 
G-DP18 3600 
G-DP22 4400 
3.1.5. Degree of labeling (DOL) 
The degree of labeling was calculated (Equation 2.3) for the FG and G-block samples selected 
as model drugs in the transdermal diffusion experiments (Table 2.3), and are presented in 
Figure 3.2. The Amax values for the samples, measured at the λmax of the respective dyes, are 
given in Appendix D. Mn was used instead of Mw in Equation (2.3) for the G-block oligomers. 
From the performed 
1
H-NMR analyses only Mn could be determined for these samples. The 
relationship Mw/Mn ≈ 2 is applicable for randomly degraded polymer chains (Smidsrød and 
Moe, 2008), but this relationship could not be used to find Mw for the two G-block samples.  
The reason for this was that the glycosidic linkages in alginate molecules are hydrolyzed by 
acids at different rates, and thus, acid hydrolysis of alginate results in a non-random 
depolymerization of the molecules (Haug et al., 1967). In a polydisperse system Mn < Mw, 
and therefore the DOL values for G-DP18 and G-DP22 were underestimated.      
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Figure 3.2: The degree of labeling of the fish gelatin peptide samples FG24 488 CASE, 
FG24 532 CASE and FG2 488 CASE, and of the two G-block samples G-DP18 488 HSS and 
G-DP22 488 HSS.   
Figure 3.2 shows a varying DOL for the different samples. In the comparison of FG24 488 
CASE, having the highest calculated DOL, with FG2 488 CASE, and G-DP18 HSS with G-
DP22 HSS, the differences in DOL between samples conjugated to the same fluorescent dye 
indicated a size dependency. Both FG2 488 CASE and G-DP22 HSS had higher DOL 
compared to FG24 488 CASE and G-DP22 HSS, respectively. A reason for this could be that 
longer peptide and oligomer chains make it possible for more Alexa Fluor
®
 fluorophores to 
react with the molecule. The lower DOL calculated for FG24 532 CASE compared to 
FG24 488 CASE may indicate a lower reactivity of the Alexa Fluor
®
 532 CASE dye, and 
thus, a lower affinity towards the primary amines in the FG peptides. 
The variations in DOL between the different samples may also be due to experimental errors, 
such as too low pH in the solution during the conjugation of FG to the amine reactive dyes. 
The amine reactive dyes bind to the primary amines in proteins via a Schiff base reaction 
(Invitrogen, 2010), but this reaction will only occur if the amine group is uncharged and 
therefore pH must be >7 in the reaction buffer.  
During transdermal diffusion, a sample with high DOL will give rise to higher fluorescence 
intensities in the tissue, due to more fluorescent dye per mole molecule, compared to a sample 
of molecules with low DOL. This is not synonymous with low DOL molecules providing 
lower penetration ability or diffusion efficiency, but rather with the fact that only the labeled 
molecules, representing only a minority of the sample, are detected in post diffusion studies.    
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The difference in DOL between samples, particularly if they are to be compared, can give 
inaccurate results in the evaluation of fluorescence intensity distribution in skin tissue, and 
therefore the fluorescence intensity values found in skin tissues after the transdermal diffusion 
experiments should be corrected for DOL. By assuming a linear correlation between DOL and 
the fluorescence intensity values obtained from post diffusion studies in human skin, 
fluorescence intensity values were corrected for DOL by using Equation (3.5). DOL 
corrections were made for FG24 488 CASE, FG24 532 CASE, FG2 488 CASE, G-DP18 488 
HSS and G-DP22 488 HSS, with the purpose to obtain a more accurate basis for evaluation of 
the transdermal diffusion studies. Throughout the rest of the report Icorrected represents the 
mean intensity value in the tissue corrected for DOL.   
mean-sample
corrected
DOL
I
I =         (3.5)    
An identical correction was made for the fluorescence intensity values measured in the 
receptor phase (IRP) for these five samples and are designated IRP corrected throughout the rest of 
the report. 
3.2. Transdermal diffusion experiments  
To study the diffusion of hydrophilic molecules into human skin a series of transdermal 
diffusion experiments were performed, and the results from the experiments are presented in 
the following sections. In sections 3.2.4, 3.2.6 and 3.2.7 the results from each single 
experiment are illustrated by a CLSM image showing the detected fluorescence in the tissue, a 
transillumination image showing the tissue structure, an intensity plot and a 3D surface plot. 
The intensity plot illustrates the detected fluorescence intensity as a function of tissue depth 
and the 3D surface plots illustrates the distribution of fluorescence intensities, and thus, the 
distribution of the test molecules in the tissue. For the diffusion kinetics experiments in 
section 3.2.5 the results are only illustrated by CLSM images and 3D surface plots. Only one 
set of images are chosen to represent each individual result. All images and raw data, for the 
line plots and mean fluorescence intensities, are given on the enclosed cd.    
From the CLSM and 3D surface plots the distribution of each test sample is described relative 
to where increase in fluorescence in the skin tissues was detected. Figure 3.3 illustrates the 
skin layers expected to be present in the tissues used in the transdermal diffusion experiments.   
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Figure 3.3: Transillumination image illustrating the skin layers in the tissues used in the 
transdermal diffusion experiments. 
In all the transdermal diffusion experiments it was detected mean fluorescence intensity 
values with very high standard deviations (SD’s). This may be due to skin heterogeneity and 
the independency between all the individual experiments that were performed. Heterogeneity 
may occur both between different or within the same body sites of an individual, and between 
identical body sites in different individuals (section 1.3), and could potentially influence the 
diffusion of molecules into human skin. For each of the experiments a new and individual 
piece of skin, with its individual pretreatment, was used. Therefore, each skin piece, from the 
same donor or not, mounted in individual Franz-type diffusion cells, gave rise to experiments 
with a high degree of independency. Holes and ruptures in the tissues, which would lead to 
black areas and falsely increase the intensity variations within the tissues, may have 
contributed to the high SD’s. It should also be remembered that the corrections for Iauto, in 
tissues with applied Alexa 488 CASE, further increased these values, in accordance with 
Equation 2.5.   
3.2.1. Control skin tissue 
The skin tissues used in the transdermal experiments gave rise to autofluorescence at 
wavelengths similar to those used in the excitation and emission of the fluorescent dye 
conjugated to the test molecules. To investigate this phenomenon control experiments were 
performed for every donor, where only the vehicle, either 60% DMSO or 10% PEG200, was 
applied on skin from each individual donor. The autofluorescence intensities and the standard 
deviations (SD’s) detected in the skins from the 9 different donors are given in Table 3.5. For 
donor A the fluorescence intensities were detected at two different wavelengths because FG 
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samples conjugated to both Alexa 488 and 532 CASE were used in the transdermal diffusion 
experiments performed on skin from that particular donor.  
Table 3.5: Autofluorescence intensities and their incident standard deviation (SD) detected 
after penetration and diffusion of only the vehicles in skin from different donors.  
Donor Excitation/emission 
wavelengths (nm) 
Vehicle applied as 
control 
Mean autofluorescence 
intensity 
SD 
A 494/517 and 530/554 60% DMSO 11/19 6/14 
B 494/517 60% DMSO 16 8 
E 494/517 60% DMSO 9 5 
F 494/517 60% DMSO 23 14 
G 494/517 10% PEG200 17 10 
H 494/517 60% DMSO 12 8 
H 494/517 10% PEG200 13 8 
I 494/517 60% DMSO 13 9 
J 494/517 60% DMSO 13 7 
K 494/517 60% DMSO 10 4 
K 494/517 10% PEG200 11 5 
 
The results from the control experiments, including CLSM and transillumination images, 
intensity plots, and 3D surface plots, will not be illustrated for each individual experiment in 
the following sections. Instead one representative control tissue has been chosen to illustrate 
the detection of autofluorescence in human skin (Figure 3.4).  
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Figure 3.4: Results of a transdermal control experiment for the detection of skin 
autofluorescence. The only substance applied on the skin was 60% DMSO. a) CLSM image 
showing the fluorescence intensity in the tissue, b) transillumination image showing the tissue 
structure, c) intensity plot with fluorescence intensity as a function of tissue depth and d) 3D 
surface plot illustrating the distribution of autofluorescence in the tissue.  
From the CLSM image (Figure 3.4a) an autofluorescence intensity (Iauto) of 14 ± 8 was 
detected. Autofluorescence in human skin is caused by a variety of known fluorophores, 
including components of the extracellular matrix (ECM), such as collagen and elastin (Section 
1.6). The results in Figure 3.3 illustrate distribution of autofluorescence predominantly in the 
dermal skin layer. This may be explained by the content of collagen and elastin in the 
papillary dermis, and the dense and collagen rich connective tissue comprising the reticular 
dermis (Mitchell and Peel, 2009). The contribution of Iauto in the transdermal diffusion 
experiments was corrected for in Imean tissue values measured after transdermal diffusion of pure 
Alexa Fluor
®
 dyes, giving corresponding Imean sample values (Equation 2.5). The contribution of 
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Iauto was not corrected for in the experiments performed with FG peptides and G-block 
oligomers because the fluorescence intensity values obtained from both the tissue and the 
receptor phase for these samples were corrected for DOL. As a consequence Iauto constituted < 
4% of the measured fluorescence intensities, and autofluorescence contributions < 5% were 
determined to be negligible.   
3.2.2. Thickness of skin from different donors 
The skin thickness measured for the skins from different donors are averages of 10 
measurements made at different sites throughout each skin sample, and are given in Table 3.6.  
Table 3.6: Skin thickness of skin from different donors used in transdermal diffusion 
experiments.  
Donor Skin thickness (mm) 
A 1.81 
B 2.18 
E 1.53 
F 2.01 
G 1.47 
H 1.55 
I 1.48 
J 1.67 
K 1.29 
 
Significant variations in skin thickness were observed between the donors, and this may have 
influenced the rate of diffusion of the test molecules through the skin. One reason for this 
variation could be that the donors with thicker skins had been or were obese. This is a 
plausible reason considering that obesity has been found to give significant skin thickening 
(Laurent et al., 2007). It is not possible to predict accurately in which layers of the skin the 
difference in thickness originate from. It was observed considerable variations in the thickness 
of hypodermis among the donors, and it was likely to believe that this was influenced by the 
amount of body fat. However, this subcutaneous fat layer was removed prior to the 
transdermal experiments and therefore did not affect the diffusion of the test molecules. The 
intercellular penetration path through SC is much longer than the 10-15 layers of corneocytes 
typically found in SC (Hadgraft, 2004), but if thicker skin is a result of a thicker SC, this may 
potentially make the penetration path even longer and thus, cause the diffusion of topical 
applied molecules to be more difficult and time-consuming. A more time-consuming 
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diffusion can also be caused by thicker viable epidermis and/or dermis. Therefore thinner skin 
may contribute to more efficient diffusion of test substances compared to thicker skin.         
The hand-operated digital slide gauge used to measure skin thickness can serve as basis for 
accurate length and thickness measurements. However, the soft tissue, particularly on the 
dermal side of the skin, made it difficult to predict if the skin was squeezed too much, giving 
lower and false skin measurements. A way to control this was to inspect whether or not the 
skin piece was immobilized in the slide gauge, but because of the soft and slippery tissue this 
was not easily determined either, and a standardized measuring method was difficult to 
obtain. In addition, the measurements could also be affected by remaining subcutaneous fat or 
stretch marks in the skin giving rise to higher or lower skin thicknesses, respectively. 
3.2.3. Maximal fluorescence intensity in the receptor phase 
The ability to penetrate the SC is an essential premise for the delivery of molecules to the 
deeper skin layers and the systemic circulation. Fluorescence in the receptor phase (IRP) could 
give an indication whether the FG peptides and G-block oligomers remained in the tissue or 
were able to diffuse through all the layers of the skin tissue. The maximum possible 
fluorescence intensity in the receptor phase (IRP max) was measured for the FG, G-block and 
pure Alexa Fluor
®
 dye test samples to provide a basis of comparison with the IRP values 
obtained after the transdermal diffusion experiments, and the results of the measurements are 
given in Table 3.7.   
Table 3.7: IRP max for the samples used in transdermal experiments. IRP max values corrected for 
DOL is also included for the FG and G-block samples conjugated to Alexa Fluor
®
 dyes.      
Sample Vehicle IRP max IRP max corrected for DOL 
FG24 488 CASE 60% DMSO 2441 321230 
FG24 488 CASE 10% PEG200 1351 177771 
FG24 532 CASE 60% DMSO 472 112449 
FG2 488 CASE 60% DMSO 1429 62130 
FG2 488 CASE 10% PEG200 2698 117299 
G-DP18 488 HSS 60% DMSO 140 32637 
G-DP18 488 HSS 10% PEG200 684 159049 
G-DP22 488 HSS 60% DMSO 230 29103 
G-DP22 488 HSS 10% PEG200 1036 131120 
Alexa 488 CASE 60% DMSO 2997 - 
Alexa 488 CASE 10% PEG200 2513 - 
Alexa 488 HSS 60% DMSO 823 - 
Alexa 488 HSS 10% PEG200 1577 - 
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3.2.4. The effect of pretreatment with laser – a pilot study 
A pilot study was performed to investigate the effect of laser pretreatment on both 
transdermal diffusion and skin viability. An overview of the three different laser treatments is 
presented in Table 2.2. The results of the experiments performed in skin tissue after 
pretreatment with FG24 488 CASE are given in Figure 3.5 and 3.6, while the results from 
identical experiments performed with FG24 532 are given in Figure 3.7 and 3.8. The mean 
fluorescence intensity (Icorrected) values detected in the different tissues are given in the text 
and are also presented in Figure 3.9, as basis of comparison between the different tissues. The 
fluorescence intensities in the receptor phases (IRP corrected) are presented in Figure 3.10. In 
addition, the results obtained from untreated skin are shown in Figure 3.9 and 3.10 (images 
and plots are not shown, but can be found on the enclosed cd).  
Figure 3.5 shows CLSM images taken after diffusion of FG24 488 CASE, giving rise to 
Icorrected values of 8314 ± 5890 and 11443 ± 6628 in the tissues after pretreatment with L1 and 
L2, respectively. This was significantly higher than the Icorrected of 3682 ± 2031 detected in the 
tissue pre-treated with L3. In the L1 and L2 pre-treated tissues a small accumulation of high 
fluorescence intensities were observed in the cavities caused by the lasers. However, in all 
three tissues FG24 488 CASE was observed to have diffused deeper into the skin, and this 
observation was supported by the intensity and 3D surface plots in Figure 3.6. The 
fluorescence distribution in the tissues after pretreatment with L1 and L2 was very similar 
(Figure 3.6a, b), while pretreatment with L3 resulted in a more even, but relatively lower 
distribution throughout the tissue (Figure 3.6c). In the L2 pre-treated tissue (Figure 3.5b) it 
was also observed a rather dominating assembly of holes in the dermis. These holes were not 
taken into account in the measurement of Icorrected, and they were considered not to have 
influenced the diffusion of FG24 488 CASE into and through the tissue, as they most likely 
were ruptures originating from cryo sectioning.    
In the experiment with FG24 532 CASE the results were different from the FG24 488 CASE 
study. Figure 3.7 shows CLSM images taken after diffusion of FG24 532 CASE, where the 
Icorrected in tissues pre-treated with L1, L2 and L3 were 9624 ± 7765, 9595 ± 7904 and 8686 ± 
6970, respectively. These values represented less variation among the three pretreatments, but 
nevertheless, L1 pretreatment resulted in the highest mean fluorescence intensity closely 
followed by L2, and then L3. The intensity and 3D surface plots, presented in Figure 3.8, 
illustrated that the test sample, to varying extent, was distributed both in the SC and in the 
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deeper dermal layers of the three tissues. From the results it was also observed that FG24 532 
CASE to a larger extent was located in the outermost barrier of SC after all three 
pretreatments compared to FG24 488 CASE.        
 
 
  
 
a) 
 
 
 
 
b) 
 
 
 
 
c) 
Figure 3.5: Results of transdermal diffusion by FG24 488 in a 60% DMSO vehicle into skin 
from donor A, after pretreatment with a) L1, b) L2 and c) L3. The CLSM images show the 
distribution of fluorescence in the tissue, and the transillumination images show the tissue 
structure.  
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Figure 3.6: Intensity plots with fluorescence intensity as a function of tissue depth and 3D 
surface plots illustrating the distribution of FG24 488 CASE in the tissue after pretreatment 
with a) L1, b) L2 and c) L3. 
 
57 
 
 
 
 
 
 
a) 
 
b) 
 
 
 
 
c) 
Figure 3.7: Results of transdermal diffusion by FG24 532 in a 60% DMSO vehicle into skin 
from donor A, after pretreatment with a) L1, b) L2 and c) L3. The CLSM images show the 
distribution of fluorescence in the tissue, and the transillumination images show the tissue 
structure.  
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c) 
Figure 3.8: Intensity plots with fluorescence intensity as a function of tissue depth and 3D 
surface plots illustrating the distribution of the FG24 532 sample in the tissue after 
pretreatment with a) L1, b) L2 and c) L3. 
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Figure 3.9: Icorrected of FG24 488 and 532 CASE in tissues pre-treated with L1, L2 and L3.  
The degree of SC barrier disruption was expected to be affected by the pulse energies and 
laser spot densities of the lasers applied in the study (Table 2.2). Upfront, it was likely to 
believe that L3 would give the highest degree of SC disruption and hence to the largest extent 
ease the diffusion of FG peptides into the skin. In the experiment, the L3 pre-treated tissues 
surprisingly resulted in the lowest Icorrected values and the lowest fluorescence distribution of 
both peptides (FG24 488 and 532 CASE) compared to L1 and L2 (Figure 3.9). An 
interpretation of these results could be that the L3 pretreatment had physically enhanced 
diffusion of the peptides to a larger extent, by creating micro-channels enabling the peptides 
to diffuse all the way through the skin. This could further indicate that L1 and L2 enhanced 
the diffusion through SC, and into the deeper skin layers, but that the rate of diffusion was 
lower. This interpretation of the results was, however, contradictory to the results from 
fluorescence measurements in the receptor phase presented in Figure 3.10. These results 
showed that 40% and 39% (relative to IRP max, Table 3.7) of applied FG24 488 CASE were 
detected to have diffused all the way through the tissues pre-treated with L1 and L2, 
compared to 28% through the tissue pre-treated with L3. For FG24 532 CASE, the results in 
Figure 3.10 show that approximately 27%, 43% and 28% of the applied samples reached the 
receptor phase in the tissues pretreated with L1, L2 and L3, respectively.  
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Figure 3.10: The fluorescence intensity in the receptor phase, IRP, measured for FG24 488 
and 532 CASE after diffusion through human abdominal skin. 
The IRP corrected values of FG24 488 CASE (Figure 3.10) indicated that approximately the same 
amount of the sample had reached the receptor phase after diffusion through skin pre-treated 
with L1 and L2, and thus, that the diffusion rate was close to equal in both tissues. A possible 
interpretation of this could be that the lower pulse energy of L1 was compensated for by a 
higher spot density, enabling the same degree of enhancement as L2, which have higher pulse 
energy, but lower spot density. However, the distribution of fluorescence was generally higher 
throughout the tissue after pretreatment with L2, which could further indicate that, even 
though longitudinal diffusion through the tissues appeared to occur at the same rates, the 
diffusion across SC and the lateral diffusion of the sample in the tissue were more profound 
after this pretreatment.        
A possible explanation of the lower Icorrected and IRP corrected found in tissues after pretreatment 
with L3 may be the extensive skin damage caused by the high laser pulse energy, leading to 
disintegration and descaling of the SC (Figure 3.5c and Figure 3.7c). Even before applying 
test samples on tissues pre-treated with L3 there were a tendency of skin descaling in the laser 
treated area. The same tendencies, although less profound, were observed for L1 and L2, but 
not in the untreated tissue. Such skin damages could possibly diminish the penetration 
through SC, and especially the diffusion into deeper skin layers in areas displaying lack of 
contact between SC and the rest of the skin. In the laser treated tissues it was also observed 
dark fields, indicating necrosis in the viable epidermis and the upper dermis (not easily seen 
in the images presented on paper). Extensive necrosis could potentially plug the pores made 
by the laser, and further result in declined or zero diffusion rates of the model drugs.  
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After evaluating these results it was concluded that all three laser pretreatments enhanced the 
diffusion of the test samples into human skin compared to what was observed for untreated 
skin. But although L2 showed the most promising enhancement effect, L1 was chosen for 
further use in transdermal diffusion experiments. This was due to this pretreatment’s ability to 
effectively penetrate the SC and allow for diffusion of the test samples deeper into the skin, 
without causing undesirable and severe damages to the skin.   
This study also provided the opportunity to investigate and understand the effect of 
autofluorescence and therefore, test samples conjugated to fluorophores with different 
excitation/emission wavelengths were used (Table 2.1). It was anticipated that background 
signals caused by autofluorescence would be reduced in the tissues at higher wavelengths in 
the confocal laser scanning microscopy. However, the opposite was observed in this study, 
and in the tissues the contribution of autofluorescence was detected to be higher for FG24 532 
CASE compared to FG24 488 CASE, as can be seen for donor A in Table 3.5. This suggests 
that even though autofluorescence generally decreases when imaging at wavelengths greater 
than 550 nm (Zeiss et al., 2012), fluorophores with excitation/emission wavelengths higher 
than 530/554 would be more appropriate when studying the impact of autofluorescence.  
3.2.5. Evaluation of skin diffusion kinetics 
The purpose of this study was to investigate the time it would take for a sample to diffuse 
through the SC and further into deeper skin layers, after pretreatment of the tissues with two 
different physical enhancement methods. The diffusion of Alexa 488 CASE and FG24 488 
CASE, each in a 60% DMSO vehicle, was studied by varying the incubation time of tissues 
pre-treated with micro-needles and L1. A total of four experiments were performed, involving 
skin tissues from three different donors. In experiments performed with micro-needles the 
incubation time varied within an interval of 2-24 hours, while the incubation time varied 
within an interval of 20 minutes-6 hours in the experiments performed with L1. The results 
from the diffusion kinetic studies are presented in the following two subsections (3.2.5.1 and 
3.2.5.2), and the experiments are summarized and further discussed in subsection 3.2.5.3.  
3.2.5.1. Diffusion kinetics in tissue pre-treated with micro-needles 
In this subsection the results of the diffusion kinetics experiments performed in skin pre-
treated with micro-needles are presented. Skins from two different donors were used in the 
experiments, due to the small sizes of the abdominal skin pieces from donor E and F. Control 
tissues from each donor are included in the results. CLSM images and 3D surface plots from 
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transdermal diffusion of Alexa 488 CASE are given in Figures 3.11 and 3.12 and in Figures 
3.15 and 3.16 for FG24 488 CASE. Tissues incubated for 2 and 6 hours were obtained from 
donor E, and tissues incubated for 12-24 hours from donor F. 
Figure 3.11: CLSM images illustrating diffusion of Alexa 488 CASE into skin tissue from 
donor E and F, after pretreatment with micro-needles. Image a) and b) are the control tissues, 
and image c) to i) represents the diffusion in skin incubated for c) 2 hours (donor E), d) 6 
hours (donor E), e) 12 hours (donor F), f) 16 hours (donor F), g) 18 hours (donor F), h) 20 
hours (donor F) and i) 24 hours (donor F). 
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a) b) c) 
d) e) f) 
g) h) i) 
Figure 3.12: 3D surface plots showing the distribution of fluorescence intensity after 
diffusion of Alexa 488 CASE into skin tissue, after pretreatment with micro-needles. a) and 
b) are the control tissues, and c) to i) represents the diffusion of Alexa 488 CASE in skin 
incubated for c) 2 hours (donor E), d) 6 hours (donor E), e) 12 hours (donor F), f) 16 hours 
(donor F), g) 18 hours (donor F), h) 20 hours (donor F) and i) 24 hours (donor F).    
Figures 3.11 and 3.12 demonstrate how Alexa 488 CASE diffused into the skin tissues after 
pretreatment with micro-needles. A minor increase in fluorescence in the tissue was observed 
after 2 hours of incubation, but most of the fluorescence was observed to be accumulated in 
the SC (Figures 3.11c and 3.12c). A similar, but varying degree of accumulation was also 
observed after 12-24 hours of incubation. After 6 hours an increase in fluorescence 
distribution both in the viable epidermis and dermis was observed, and the highest and most 
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evenly distributed fluorescence intensity was observed throughout the tissue after 12 hours of 
incubation (Figures 3.11 and 3.12 d, e). After 16 hours it was observed a decrease in 
fluorescence intensity, and even though there were some variance between tissues incubated 
for 16-24 hours, they all displayed lower fluorescence intensities distributed throughout the 
tissues (Figures 3.11 and 3.12 f-i).  
In the tissues incubated for 2, 18 and 24 hours, Alexa 488 CASE was observed to be 
distributed in a fashion that resembled narrow pillars, spanning from the SC and into deeper 
layers of the tissues (Figure 3.12c, h, i). This pattern of diffusion was suggested to be caused 
by inconsistent barrier disruption after pretreatment with the manually operated micro-needle 
device, further discussed in section 3.2.10. Thus, these results illustrated the need for 
sufficient penetration of the SC to enable diffusion of the test sample deeper into the tissue. In 
these three tissues it was also observed that lateral diffusion of Alexa 488 CASE only 
occurred to a minor degree in the deeper dermal layer. An interpretation of this observation 
could be that micro-pores, created by the micro-needles, not only enabled diffusion through 
the outermost barrier, but also had an impact on the direction of diffusion deeper into the skin.       
The Imean-sample detected in tissues incubated for 2-24 hours is presented as function of 
incubation time in Figure 3.13, together with the Imean control in the tissues from both donors. 
The Imean-tissue and Imean-sample values are given in Table E.1 in Appendix E.        
 
Figure 3.13: Imean control detected in the control tissues from donor E and F, and Imean sample 
values of Alexa 488 CASE detected in tissues after 2-24 hours of incubation.  
Figure 3.13 supports the observation of increased fluorescence in the tissue already after 6 
hours, and that a peak in mean fluorescence intensity was achieved after 12 hours. 
0 
50 
100 
150 
200 
250 
Control 
Donor E 
Control 
Donor F 
2 6 12 16 18 20 24 M
ea
n
 f
lu
o
re
sc
en
ce
 i
n
te
n
si
ty
 
Incubation time (hours) 
65 
 
Interestingly, the tissue incubated for 6 hours displayed higher intensity values compared to 
the tissues incubated for 16-24 hours. This could be due to that the tissues originated from two 
different donors with varying skin thickness. In addition, the heterogeneity in tissues from the 
same donor may have contributed both to the variation in diffusion efficiency into the skin 
tissues and the high standard deviations (SD’s) observed in figure 3.13 (discussed in section 
3.2).  
The IRP values measured in the receptor phases are given in Figure 3.14. After 12 hours of 
incubation an IRP value of 7 was measured, corresponding to only 0.23% of IRP max (Table 3.7). 
This could mean that, even though a peak in Imean sample and an extended distribution of Alexa 
488 CASE were observed after 12 hours, the diffusion rate was lower than 0.17 mm/hour 
(tissue thickness/hours of incubation). Therefore, a longer incubation time would likely result 
in diffusion of the sample through the skin and into the receptor phase. A high Imean sample and 
low IRP could also indicate a high degree of lateral diffusion of the sample in the tissue. The 
highest IRP value was measured after 20 hours of incubation, supporting the suggested need 
for longer incubation time to reach the receptor phase. However, the IRP value corresponded 
to 8% of IRP max, and thus only a minor portion of the sample was detected to have diffused all 
the way through the skin.  
In general, the IRP values were highly inconsistent, and showed no logical trend that could be 
correlated to the Imean-sample values and the distribution of Alexa 488 CASE in the tissues. The 
IRP value obtained after 2 hours was higher compared to after 6, 12, 18 and 24 hours, and the 
IRP value after 24 hours was lower compared to in the control experiment (donor F), 
indicating that the fluorescence was likely to be a result of autofluorescence caused by skin 
constituents. The inconsistency indicated unreliable measurements, which could be due to 
experimental errors, further discussed in subsection 3.2.5.3. 
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Figure 3.14: The fluorescence intensity in the receptor phase, IRP, measured for the control 
tissues and for Alexa 488 CASE after 2-24 hours of incubation. 
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Figure 3.15: CLSM pictures illustrating diffusion of FG24 488 CASE into skin tissues from 
donor E and F, after pretreatment with micro-needles. The pictures a) and b) are the control 
tissues, and c) to i) represents the diffusion of FG24 488 CASE in skin incubated for c) 2 
hours (donor E), d) 6 hours (donor E), e) 12 hours (donor F), f) 16 hours (donor F), g) 18 
hours (donor F), h) 20 hours (donor F) and i) 24 hours (donor F).    
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a) b) c) 
d) e) f) 
g) h) i) 
Figure 3.16: Surface plot showing the distribution of fluorescence intensity after diffusion of 
FG24 488 CASE into skin tissues from donor E and F, after pretreatment with micro-needles. 
a) and b) are the control tissue, and c) to i) represents the diffusion of Alexa 488 CASE in 
skin incubated for c) 2 hours (donor E), d) 6 hours (donor E), e) 12 hours (donor F), f) 16 
hours (donor F), g) 18 hours (donor F), h) 20 hours (donor F) and i) 24 hours (donor F).    
Figures 3.15 and 3.16 demonstrate how FG24 488 CASE diffused into skin tissues after 
pretreatment with micro-needles. In tissue from donor E, incubated for 2 and 6 hours, the 
distribution of fluorescence was concentrated in SC and no fluorescence indicating diffusion 
of FG24 488 CASE deeper into the tissue was observed (Figure 3.15c, d). These observations 
were supported by the 3D surface plots (Figure 3.16c, d). After 12 and 16 hours high 
fluorescence intensities were observed in the SC, but the applied sample was also observed to 
69 
 
be distributed deeper in the tissue (Figure 3.15d,e). The highest and most evenly distributed 
dermal fluorescence was observed after 16 hours (Figure 3.16e). At the same time this tissue 
displayed lower intensities in the viable epidermis compared to in the dermis, indicating that 
FG24 488 CASE was able to readily diffuse through the epidermal layer after overcoming the 
SC barrier. After 18, 20 and 24 hours of incubation a decrease in fluorescence were observed, 
both in the SC and in deeper in the tissues (Figures 3.15 and 3.16 g, h, i).  
Icorrected, detected in the tissues after 2-24 hours of incubation, is presented as a function of 
incubation time in Figure 3.17, and the Icorrected values are given in Table E.2 in Appendix E. 
 
Figure 3.17: Icorrected values of FG24 488 detected in tissues incubated for 2-24 hours.  
Figure 3.17 supports the observations of increasing fluorescence with increasing incubation 
time in the time interval of 2-16 hours of incubation, and show that a peak in Icorrected for 
FG24 488 CASE was achieved after 16 hours. It also illustrates a decrease in Icorrected with 
increasing incubation time after 18-24 hours. The tissue incubated for 12 hours displayed 
higher intensity values compared to the tissues incubated for 20 and 24 hours, and this 
variation may have been due to the heterogeneity of each individual piece of tissue. Possible 
reasons for the variations in Icorrected are discussed in subsection 3.2.5.3.    
The IRP values measured after 2-24 hours of incubation are given in Figure 3.18. After 16 
hours of incubation an increase in fluorescence in the receptor phase was observed, but this 
increase only corresponded to 0.3% of IRP max. This was similar to the results obtained for 
Alexa 488 CASE, and indicated that the rate of diffusion in the longitudinal direction was < 
12.5 mm/hour. Increase in IRP corrected was also observed after 20 hours (0.4 % of IRP max), and 
after 24 hours the highest value was measured. The IRP corrected did, however, only correspond 
0 
2000 
4000 
6000 
8000 
10000 
12000 
14000 
2 6 12 16 18 20 24 
I c
o
r
re
c
te
d
 
Incubation time (h) 
70 
 
to 3% of IRP max. A minor degree of inconsistency was observed for the IRP corrected values of 
FG24 488 CASE, including the lower value measured after 18 hours compared to after 16 
hours. The reasons for this inconsistency were believed to be the same as for Alexa 488 
CASE, discussed in subsection 3.2.5.3.    
 
Figure 3.18: The IRP corrected values measured for FG24 488 CASE after 2-24 hours of 
incubation. 
3.2.5.2. Diffusion kinetics in skin pre-treated with laser 
In this subsection the results of the diffusion kinetics experiments performed in skin pre-
treated with L1 (Table 2.2) are presented. CLSM images and 3D surface plots illustrating 
diffusion of Alexa 488 CASE in human skin tissues incubated for 20 minutes-6 hours are 
given in Figures 3.19 and 3.20. CLSM images and 3D surface plots illustrating diffusion of 
FG24 488 CASE in skin under identical terms, are given in Figures 3.23 and 3.24. The control 
tissue from donor J is included in the results.  
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Figure 3.19: CLSM pictures illustrating diffusion of Alexa 488 CASE into skin tissue from 
donor J, after pretreatment with L1. Picture a) is the control tissue, b) to f) shows the diffusion 
of Alexa 488 incubated for b) 20 min, c) 40 min, d) 60min, e) 2 hours and f) 6 hours. 
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a) 
 
b) 
 
c) 
 
d) 
 
e) 
 
f) 
Figure 3.20: Surface plot illustrating the distribution of fluorescence intensity after diffusion 
of Alexa 488 CASE into skin tissues from donor J, after pretreatment with L1. Picture a) is 
the control tissue, b) to f) shows the diffusion of Alexa 488 incubated for b) 20 min, c) 40 
min, d) 60min, e) 2 hours and f) 6 hours. 
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Figures 3.19 and 3.20 demonstrate an increase in fluorescence intensity distribution with 
increasing incubation time. After 20 minutes of incubation high intensity fluorescence was 
observed to be distributed throughout the epidermis (Figure 3.19b and 3.20b). The distribution 
of Alexa 488 CASE was observed to increase deeper into the tissue with increasing 
incubation time between 40 minutes-6 hours of incubation (Figure 3.19 and 3.20). After 6 
hours the highest fluorescence intensities were observed to be distributed in the SC and 
evenly throughout the dermal layer. At the same time this tissue displayed lower intensities in 
the viable epidermis compared to in the dermis (Figures 3.19f and 3.20f), as was observed for 
FG24 488 CASE after pretreatment with micro-needles and 16 hours of incubation 
(subsection 3.2.5.1). Thus, disruption of the SC barrier enabled Alexa 488 CASE to readily 
diffuse through the epidermis and into the dermis.  
Imean sample of Alexa 488 CASE, detected in tissues after 20 minutes-6 hours of incubation, is 
presented as a function of incubation time in Figure 3.21. The Imean tissue and Imean sample values 
are given in Table E.3, in Appendix E. 
 
Figure 3.21: Imean control detected in the control tissue from donor J, and Imean sample values of 
Alexa 488 CASE detected in tissues after 20 minutes-6 hours of incubation.  
Figure 3.21 clearly illustrates an increase in Imean sample with increasing incubation time, and 
demonstrates that the highest mean fluorescence intensity in the tissues was obtained after 6 
hours of incubation (Figures 3.19f and 3.20f). This could imply that 6 hours of incubation was 
sufficient for diffusion of the sample all the way through the tissue and into the receptor 
phase. The IRP measurements, given in Figure 3.22, somewhat confirmed this implication, as 
the only increase in fluorescence intensity in the receptor phase was observed after this 
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incubation time. However, the measured IRP value only corresponded to 1 % of IRP max, which 
once again emphasized that a high Imean sample and an even distribution of the sample 
throughout the deeper layers of the tissue was not equivalent with efficient diffusion into the 
receptor phase. The diffusion rate was therefore suggested to be < 0.28 mm/hour. This 
diffusion rate was higher compared to the ones suggested for diffusion of Alexa 488 CASE 
and FG24 488 CASE through skin tissues and into the receptor phase after pretreatment with 
micro-needles, given in subsection 3.2.5.1. The IRP values measured after 40 minutes-2 hours 
were equal to the IRP from the control tissue, and after 20 minutes it was even lower (one 
decimal used to indicate value > 0), indicating the presence of endogenous fluorophores in the 
receptor phase giving rise to autofluorescence.   
 
Figure 3.22: The fluorescence intensity in the receptor phase, IRP, measured for the control 
tissue and for Alexa 488 CASE after 20 minutes - 6 hours of incubation. 
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Figure 3.23: CLSM pictures illustrating diffusion of FG24 488 CASE into skin tissue from 
donor J, after pretreatment with L1. Picture a) is the control tissue, b) to f) shows the diffusion 
of FG24 488 incubated for b) 20 min, c) 40 min, d) 60min, e) 2 hours and f) 6 hours. 
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a) 
 
b) 
 
c) 
 
d) 
 
e) 
 
 
f) 
Figure 3.24: Surface plot illustrating the distribution of fluorescence intensity after diffusion 
of FG24 488 CASE into skin tissue from donor J, after pretreatment with L1. Picture a) is the 
control tissue, b) to f) shows the diffusion of FG24 488 incubated for b) 20 min, c) 40 min, d) 
60min, e) 2 hours and f) 6 hours. 
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Figures 3.23 and 3.24 show how the distribution of fluorescence increased with increasing 
incubation time as a result of diffusion of FG24 488 CASE in skin tissues. This trend was 
similar to what was found for Alexa 488 CASE in skin tissues after pretreatment with L1, but 
the progression of diffusion seemed to be slower for the FG peptide sample. After 20 minutes 
of incubation high intensity fluorescence was observed to be distributed in the upper part of 
epidermis, and after 40 minutes FG24 488 CASE was primarily distributed throughout the 
layers of epidermis (Figures 3.23 and 3.24 b, c). An increasing distribution of high intensity 
fluorescence in both epidermis and in the upper dermis was observed after 1 and 2 hours of 
incubation, indicating diffusion of FG24 488 CASE beyond the SC and the viable epidermis, 
and into the dermis (Figures 3.23 and 3.24 d, e). The highest overall distribution of FG24 488 
CASE was observed after 6 hours of incubation (Figure 3.23f and 3.24f).  
In the tissue incubated for 6 hours (Figure 3.23f) a large cavity, caused by the laser treatment, 
was observed to span both the SC and the viable epidermis. Similar cavities were also 
observed in other tissues with this pretreatment. However, in this particular tissue, the 
distribution of high fluorescence intensities was observed to expand from the laser cavity to 
deeper layers of the dermis, while fluorescence was observed in the SC in the areas where the 
skin barrier was intact and deeper in the underlying dermis. An interpretation of this 
observation was that the diffusion of FG24 488 CASE primarily occurred through the cavity 
in the outer layers of the skin, and that lateral diffusion of FG24 488 CASE contributed to a 
more extensive distribution of the sample throughout the dermis.  
Icorrected of FG24 488 CASE, detected in tissues after 20 minutes-6 hours of incubation, is 
presented as a function of incubation time in Figure 3.25. The Icorrected values are given in 
Table E.4, in Appendix E. 
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Figure 3.25: Icorrected values of FG24 488 detected in tissues after 20 minutes-6 hours of 
incubation.  
Figure 3.25 shows the trend of increasing Icorrected values with increasing incubation time, and 
that the highest mean fluorescence was obtained after 6 hours of incubation. The IRP 
measurements, given in Figure 3.26, showed the greatest increase in fluorescence intensity in 
the receptor phase after 6 hours of incubation, corresponding to 1.8% of IRP max. The diffusion 
rate was therefore suggested to be < 0.28 mm/hour, the same as for Alexa 488 CASE in skin 
tissue after the same incubation time. However, the increase in IRP measured after 1 hour, 
corresponding to 1.5% IRP max, introduced a degree of inconsistency in the measurements. 
Possible reasons for this inconsistency are discussed in subsection 3.2.5.3.      
 
Figure 3.26: The IRP corrected values measured for FG24 488 CASE after 20 minutes-6 hours of 
incubation. 
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3.2.5.3. Summary of skin diffusion kinetics experiments 
The diffusion kinetics of Alexa 488 CASE and FG24 488 CASE in skin tissues pre-treated 
with micro-needles and L1 are collectively compared and discussed in this subsection. The 
results of the kinetics experiments indicated the need for 12 and 6 hours of incubation to 
achieve the greatest distribution of Alexa 488 CASE throughout the skin tissues, after 
pretreatment with micro-needles and L1, respectively. For FG24 488 CASE the greatest 
distribution of fluorescence was achieved after 16 hours in skin pre-treated with micro-
needles and 6 hours in skin pre-treated with L1.  
The different incubation times needed for distribution throughout the tissues between the two 
samples may have been due to their differences in Mw. Bos and Meinardi (2000) introduced 
the “500 Dalton rule”, and stated that passive skin absorption starts to decline rapidly around 
500 Dalton (g/mol) due to molecular size in untreated skin. The Mw of Alexa 488 CASE is 
around 650 g/mol (Table 2.1), and thus it is likely to assume that Alexa 488 CASE diffuse 
into skin more rapidly compared to FG24 488 CASE, with an estimated Mw of 3000 g/mol. 
Da Silva et. al (2008) reported significant ex vivo skin penetration of taurin, a hydrophilic 
amino acid with a molecular weight of 125.48 g/mol, in untreated human breast skin after 1 
hour. In comparison, the longer time needed for distribution of Alexa 488 CASE and 
FG24 488 CASE into deeper skin layers demonstrated the need for longer incubation time 
with increasing molecular weight. However, the results reported here were obtained from skin 
tissues where penetration through the outer skin barrier was physically enhanced, by the use 
of micro-needles and laser, prior to application of samples. Therefore, it cannot be assumed 
that a longer incubation time alone would be sufficient to achieve diffusion of larger 
molecules through untreated skin. However, for the following transdermal diffusion 
experiments it was introduced a standard incubation time of 22 hours. A longer incubation 
time was considered to be favorable for the use of test molecules of higher Mw compared to 
FG24 488 CASE. In addition, a longer incubation time could possibly provide the opportunity 
to study diffusion both into and all the way through human skin. 
The effect of Mw in penetration of the SC should imply that FG24 488 CASE would be 
retained in the SC to a larger extent compared to Alexa 488 CASE.  However, from the results 
after diffusion of the samples in skin tissues pre-treated with micro-needles (Figures 3.11 and 
3.15), Alexa 488 CASE was observed to be more accumulated in the SC compared to 
FG24 488 CASE. This observation was most profound in tissues incubated for 18-24 hours. A 
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reason for this could be a varying degree of barrier disruption by the micro-needle device, 
discussed in section 3.2.10. Another explanation could be that, even though the SC barrier 
was disrupted, the higher Mw of FG24 488 resulted in slower diffusion into and through the 
SC compared to Alexa 488 CASE, leaving more of the sample to be wiped off on the skin 
surface after the given incubation time.  
In the experiment performed with micro-needles and L1, the time span between each chosen 
time of incubation was not identical. This might have affected the results from the 
experiments performed with laser more profoundly, as the time span was increased from 
being 20 minutes during the first hour of incubation to 4 hours between 2 and 6 hours of 
incubation. Identical incubation time (6 hours) was observed to give the highest mean 
fluorescence intensities and the greatest distribution throughout the tissues after pretreatment 
with L1 for both Alexa 488 CASE and FG24 488 CASE. If assuming a correlation between 
Mw and incubation time, a shorter incubation time would be expected for Alexa 488 CASE 
compared to FG24 488. It can therefore be questioned if the highest Imean sample of Alexa 488 
CASE was reached at an earlier time within this time span of 4 hours. Inclusion of an 
additional incubation time within the interval of 2-6 hours could perhaps have revealed this, 
while inclusion of an extra incubation time exceeding 6 hours could give an indication of 
whether or not the highest fluorescence distribution in fact was reached for both samples after 
6 hours. 
The skin tissues pre-treated with micro-needles were obtained from two different donors, and 
the average thickness of the two tissues varied, as shown in Table 3.6. Skin from donor F was 
measured to be 0.48 mm thicker than skin from donor E, which means that the longitudinal 
diffusion path towards the deeper skin layers and ultimately the receptor phase, were much 
longer for samples applied on skin from donor F. This may have influenced the results, and 
thus the interpretation of the diffusion kinetics of Alexa 488 CASE and FG24 488 CASE. In 
the experiments with applied Alexa 488 CASE this difference in skin thickness could likely 
be the reason why the tissue incubated for 6 hours displayed higher intensity values compared 
to the tissues incubated for 16-24 hours. The thinner skin of donor E may also have been the 
reason behind the higher IRP values measured after 2 hours compared to after longer 
incubation times for Alexa 488 CASE, and the higher IRP values after 6 hours compared to 
after 12 hours for FG24 488 CASE.  Skin tissues prepared from one individual donor are 
likely to display a varying degree of heterogeneity. This may include varying thickness and 
nature of the SC throughout the skin of one single individual, but also visible variations, such 
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as stretch marks and amount and density of skin appendages. This could potentially influence 
the diffusion efficiency in the different skin tissues, and thus, also have influenced the results 
from the receptor phases. Skin heterogeneity is also mentioned in section 1.3 and 3.2.  
The inconsistency observed in the IRP measurements may have been caused by experimental 
errors. Contact between the skin pieces and the PBS buffer in the Franz cells is a requirement 
for efficient diffusion into the skin tissues and the receptor phase. Lack of such contact could 
be due to insufficient tightening of the screw clamps used to mount together the experimental 
set ups, and air bubbles in the interface between the skin tissue and the PBS buffer. In 
addition, spillage of excess sample from the epidermal surface of the tissues after incubation 
and into the receptor phase during dismounting of the Franz-cells, may have contributed to 
higher fluorescence in this phase in some experiments. Insufficient removal of the 
subcutaneous fat could also restrict, and even prevent, molecules from diffusing into the 
receptor phase, and thus give rise to incorrect IRP measures.  
The results of the diffusion kinetics experiments showed that Alexa 488 CASE was able to 
efficiently diffuse into human skin. Therefore, the fluorophore, conjugated to FG peptides, 
was not expected to cause any negative effects on the diffusion into skin tissues. Since only 
the Alexa 488 CASE fluorophore was studied, it could only be assumed that the same was 
true for Alexa 488 HSS bound to the G-block oligomers. The fluorophores would, however, 
contribute to a minor increase in Mw, which could further decrease the diffusion efficiency of 
the test molecules into human skin.  
3.2.6. Diffusion experiments – fish gelatin peptides 
The two FG peptides FG24 488 CASE and FG2 488 CASE were used to study diffusion of 
peptides into the skin (Table 2.3). Diffusion of each sample was studied in a total of 6 
experiments. Two different vehicles, 60% DMSO and 10% PEG200, were used separately to 
investigate the diffusion through untreated skin and through skin pre-treated with micro-
needles and L1. The skin tissues were obtained from different donors, as given in Table 2.3. 
The results from the transdermal diffusion experiments of FG24 488 CASE and FG2 488 
CASE are given in subsection 3.2.6.1 and 3.2.6.2, respectively, and both are summarized in 
subsection 3.2.6.3.  
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3.2.6.1. FG24 488 CASE 
Transdermal diffusion of FG24 488 CASE in untreated skin 
The results obtained from transdermal diffusion of FG24 488 CASE in a 60% DMSO and in a 
10% PEG200 vehicle into untreated skin from donor H, are given in Figures 3.27 and 3.28, 
respectively.     
 
a) 
 
b) 
   
 
 
 
 
 
 
 
 
c)   d) 
Figure 3.27: Results of transdermal diffusion by FG24 488 in a 60% DMSO vehicle into 
untreated skin from donor H. a) CLSM image showing the fluorescence intensity in the tissue, 
b) transillumination image showing the tissue structure, c) intensity plot where fluorescence 
intensity is given as a function of tissue depth and d) 3D surface plot illustrating the 
distribution of the FG24 488 sample in the tissue.  
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c)   d) 
Figure 3.28: Results of transdermal diffusion by FG24 488 in a 10% PEG200 vehicle in 
untreated skin from donor H. a) CLSM image showing the fluorescence intensity in the tissue, 
b) transillumination image showing the tissue structure, c) intensity plot with fluorescence 
intensity as a function of tissue depth and d) 3D surface plot illustrating the distribution of the 
FG24 488 sample in the tissue. 
Figure 3.27 demonstrates how FG24 488 CASE in a 60% DMSO vehicle was distributed in 
the tissue after diffusion. Icorrected of FG24 488 CASE was detected to be 3225 ± 3450. From 
the CLSM image (Figure 3.27a) it was observed that the detected fluorescence predominantly 
was located in the SC. This observation was supported by the intensity and the surface plots 
(Figure 3.27 c, d). However, the surface plot also indicated a minor increase in distribution of 
the sample in the dermal layer compared to the control tissue (results from the control tissue 
are given on the enclosed cd). The two single intensity peaks observed in the lower left corner 
of the surface plot (Figure 3.267) may be due to tissue fragments torn off from the tissue 
during cryo sectioning.  
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Figure 3.28 illustrates the results after transdermal diffusion of FG24 488 CASE in a 10% 
PEG200 vehicle. The distribution of fluorescence was observed to be similar to the one seen 
for the sample in a 60% DMSO vehicle, illustrated in Figure 3.28a. However, the detected 
fluorescence intensities were lower for FG24 488 CASE in a 10% PEG200 vehicle, as can be 
seen by comparing the results from these two experiments (Figures 3.27 and 3.28 c, d). This 
observation was also supported by the Icorrected, detected to be 2350 ± 2174. The observations 
of fluorescence being predominantly located in the SC may indicate the ability of FG24 488 
CASE to passively diffuse into this outermost skin layer. However, the sample seemed to be 
retained in SC and thus, further diffusion into deeper layers was apparently restricted.  
Transdermal diffusion of FG24 488 CASE in skin after pretreatment with micro-needles 
The results obtained from transdermal diffusion of FG24 488 CASE in a 60% DMSO vehicle 
and in a 10% PEG200 vehicle into skin from donor H, after pretreatment with micro-needles, 
are given in Figures 3.29 and 3.30, respectively.    
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b) 
 
c)   d) 
Figure 3.29: Results of transdermal diffusion by FG24 488 in a 60% DMSO vehicle in skin 
from donor H, after pretreatment with micro-needles. a) CLSM image showing the 
fluorescence intensity in the tissue, b) transillumination image showing the tissue structure, c) 
intensity plot with fluorescence intensity as a function of tissue depth and d) 3D surface plot 
illustrating the distribution of the FG24 488 sample in the tissue.  
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c)   d) 
Figure 3.30: Results of transdermal diffusion by FG24 488 in a 10% PEG200 vehicle in skin 
from donor H, after pretreatment with micro-needles. a) CLSM image showing the 
fluorescence intensity in the tissue, b) transillumination image showing the tissue structure, c) 
intensity plot with fluorescence intensity as a function of tissue depth and d) 3D surface plot 
illustrating the distribution of the FG24 488 sample in the tissue.  
Figure 3.29 demonstrates how FG24 488 CASE, applied in a 60% DMSO vehicle, was 
distributed in the tissue after diffusion. Fluorescence was observed to be predominantly, but 
unevenly, distributed in the SC (Figure 3.29 a, d). The Icorrected of FG24 488 CASE was 
detected to be 2513 ± 2790. Although the higher distribution of fluorescence in SC most 
likely constituted the majority of this detected mean fluorescence, the results from the 
experiment indicated that FG24 488 CASE to a minor degree was able to diffuse through the 
SC and deeper into the skin (Figure 3.29d).  
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Figure 3.30 illustrates the results from transdermal diffusion of FG24 488 CASE in a 10% 
PEG200 vehicle. The Icorrected for the sample was detected to be 6808 ± 4349, a value 
considerably higher than the one found after diffusion of the sample in a 60% DMSO vehicle. 
The fluorescence was observed to be distributed both in the SC and throughout the skin with 
varying intensities (Figure 3.30a). Distribution, and thus diffusion, of FG24 488 CASE deeper 
into the tissue was confirmed by the intensity and surface plots (Figure 3.30 c, d). In the 
viable epidermis and the underlying upper dermis considerably lower intensities was observed 
compared to in the SC and deeper into the dermis. This may indicate that after overcoming the 
SC barrier, FG24 488 CASE was able to diffuse more readily deeper into the tissue, which 
was indicated in the diffusion kinetics experiments also (section 3.2.5).   
Transdermal diffusion of FG24 488 CASE in skin after pretreatment with L1 
The results obtained from transdermal diffusion of FG24 488 CASE in a 60% DMSO vehicle 
into skin from donor B and FG24 488 CASE in a 10% PEG200 vehicle into skin from donor 
K, after pretreatment with L1, are given in Figures 3.31 and 3.32, respectively. 
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c)   d) 
Figure 3.31: Results of transdermal diffusion by FG24 488 in a 60% DMSO vehicle in skin 
from donor B, after pretreatment with L1. a) CLSM image showing the fluorescence intensity 
in the tissue, b) transillumination image showing the tissue structure, c) intensity plot with 
fluorescence intensity as a function of tissue depth and d) 3D surface plot illustrating the 
distribution of the FG24 488 sample in the tissue.  
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c)   d) 
Figure 3.32: Results of transdermal diffusion by FG24 488 in a 10% PEG200 vehicle in skin 
from donor K, after pretreatment with L1. a) CLSM image showing the fluorescence intensity 
in the tissue, b) transillumination image showing the tissue structure, c) intensity plot with 
fluorescence intensity as a function of tissue depth and d) 3D surface plot illustrating the 
distribution of the FG24 488 sample in the tissue.  
Figure 3.31 demonstrates how FG24 488 CASE in a 60% DMSO vehicle was distributed in 
the skin tissue. The highest fluorescence intensities were observed in the areas of SC where 
the barrier was intact and in the cavities originating from the laser treatment (Figure 3.31a). 
However, relatively high fluorescence intensities were also observed in the rest of the tissue 
(Figure 3.31 c, d), and the Icorrected for FG24 488 CASE was detected to be 13102 ± 6479. 
Figure 3.32 demonstrates that FG24 488 CASE in a 10% PEG200 vehicle was able to diffuse 
more efficiently into the skin tissue compared to the same sample applied in a 60% DMSO 
vehicle. In this experiment Icorrected for FG24 488 CASE was detected to be 18885 ± 10003. 
High fluorescence intensities were observed throughout the tissue, especially in and around 
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the laser cavity (Figure 3.32a), and the observations were supported by both the intensity and 
the surface plots (Figure 3.32 c, d).     
3.2.6.2. FG2 488 CASE    
Transdermal diffusion of FG2 488 CASE in untreated skin 
The results obtained from transdermal diffusion of FG2 488 CASE in a 60% DMSO and in a 
10% PEG200 vehicle, into untreated skin from donor H, are given in Figures 3.33 and 3.34, 
respectively. 
 
a) 
 
b) 
    
 
 
 
 
 
 
 
 
 
c)   d) 
Figure 3.33: Results of transdermal diffusion by FG2 488 in a 60% DMSO vehicle into 
untreated skin from donor K. a) CLSM image showing the fluorescence intensity in the tissue, 
b) transillumination image showing the tissue structure, c) intensity plot with fluorescence 
intensity as a function of tissue depth and d) 3D surface plot illustrating the distribution of the 
FG2 488 sample in the tissue.  
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c)   d) 
Figure 3.34: Results of transdermal diffusion by FG2 488 in a 10% PEG200 vehicle into 
untreated skin from donor K. a) CLSM image showing the fluorescence intensity in the tissue, 
b) transillumination image showing the tissue structure, c) intensity plot with fluorescence 
intensity as a function of tissue depth and d) 3D surface plot illustrating the distribution of the 
FG2 488 sample in the tissue.  
Figure 3.33 demonstrates how FG2 488 CASE in a 60% DMSO vehicle was distributed in the 
tissue after diffusion. From the CLSM image (Figure 3.33a) very little fluorescence was 
observed, and Icorrected was detected to be 407 ± 440. The low Icorrected value seemed to be a 
result of the weak fluorescence observed in the SC. Diffusion of the sample deeper into the 
tissue was not observed, an observation supported by the intensity and surface plots (Figure 
3.33 c, d). Figure 3.34 illustrates the results after diffusion experiments with FG2 48 CASE 
applied in a 10% PEG200 vehicle. Icorrected was detected to be 554 ± 365, which was somewhat 
higher compared to what was found for the sample in a 60% DMSO vehicle. However, less 
fluorescence was observed in the SC (Figure 3.34a), and the intensity and surface plots 
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(Figure 3.34 c, d) indicated fluorescence deeper in the skin. Because of the Mw of the sample 
(Table 3.3) and the weak fluorescence intensities observed in the SC, it was assumed that the 
fluorescence detected in the deeper skin layers was autofluorescence, distributed in the dermal 
layer of this individual skin sample, rather than a result of diffusion of FG2 488 CASE.    
Transdermal diffusion of FG2 488 CASE in skin after pretreatment with micro-needles 
The results obtained from transdermal diffusion of FG2 488 CASE in a 60% DMSO and in a 
10% PEG200 vehicle into skin from donor K, after pretreatment with micro-needles, are 
given Figures 3.35 and 3.36, respectively. 
 
a) 
 
b) 
   
 
 
 
 
 
 
c)   d) 
Figure 3.35: Results of transdermal diffusion by FG2 488 in a 60% DMSO vehicle into skin 
from donor K, after pretreatment with micro-needles. a) CLSM image showing the 
fluorescence intensity in the tissue, b) transillumination image showing the tissue structure, c) 
intensity plot with fluorescence intensity as a function of tissue depth and d) 3D surface plot 
illustrating the distribution of the FG2 488 sample in the tissue.  
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c)   d) 
Figure 3.36: Results of transdermal diffusion by FG2 488 in a 10% PEG200 vehicle into skin 
from donor K, after pretreatment with micro-needles a) CLSM image showing the 
fluorescence intensity in the tissue, b) transillumination image showing the tissue structure, c) 
intensity plot with fluorescence intensity as a function of tissue depth and d) 3D surface plot 
illustrating the distribution of the FG2 488 sample in the tissue.  
Figure 3.35 demonstrates the distribution of FG2 488 CASE in a DMSO vehicle in the skin 
tissue after the diffusion experiment. Fluorescence intensities were observed both in the SC 
and deeper into the tissue, and Icorrected for FG2 488 CASE was detected to be 1631 ± 993. The 
intensity and surface plots (Figure 3.35 a, d) both illustrated that more fluorescence was 
distributed in one particular area of the SC. A minor cavity was observed in the SC in this 
area (Figure 3.35b) and was likely to be a result of penetration into SC by the micro-needle 
device. Because fluorescence also was observed to be distributed deeper into the tissue it was 
suggested that FG2 488 CASE, to some extent, was able to penetrate the SC and diffuse 
deeper into skin after pretreatment with micro-needles.  
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Diffusion of FG2 48 CASE in a 10% PEG vehicle resulted in an accumulation of the sample 
in the SC (Figure 3.36a). Distribution of fluorescence was not easily observed in the deeper 
layers of the tissue. The intensity and surface plots (Figure 3.36 c, d) both supported the 
observation of fluorescence accumulated in the SC, but also indicated a minor distribution 
deeper into the tissue. The Icorrected of FG2 488 CASE was detected to be 1248 ± 1498, and the 
transillumination image (Figure 3.36b) showed perforations in the SC, suggesting that this 
sample could be able to diffuse through the barrier and deeper into the skin. But, even though 
the micro-needle pretreatment penetrated the skin barrier, and thus potentially overcame the 
size limitations associated with the SC barrier, the results presented here did not indicate 
efficient diffusion of FG2 488 CASE into the skin.                   
Transdermal diffusion of FG2 488 CASE in skin after pretreatment with L1 
The results obtained from transdermal diffusion of FG2 488 CASE in a 60% DMSO and a 
10% PEG200 vehicle into skin from donor K, after pretreatment with L1, are given in Figures 
3.37 and 3.38, respectively. 
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c)   d) 
Figure 3.37: Results of transdermal diffusion by FG2 488 in a 60% DMSO vehicle into skin 
from donor K, after pretreatment with laser a) CLSM image showing the fluorescence 
intensity in the tissue, b) transillumination image showing the tissue structure, c) intensity 
plot with fluorescence intensity as a function of tissue depth and d) 3D surface plot 
illustrating the distribution of the FG2 488 sample in the tissue.  
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c)   d) 
Figure 3.38: Results of transdermal diffusion by FG2 488 in a 10% PEG200 vehicle into skin 
from donor K, after pretreatment with laser a) CLSM image showing the fluorescence 
intensity in the tissue, b) transillumination image showing the tissue structure, c) intensity 
plot with fluorescence intensity as a function of tissue depth and d) 3D surface plot 
illustrating the distribution of the FG2 488 sample in the tissue.  
Figure 3.37 demonstrates how FG2 488 CASE in a 60% DMSO vehicle was distributed in the 
skin tissue after diffusion. FG2 488 CASE was observed to be distributed with the highest 
fluorescence intensities in the laser cavities and deeper into the surrounding tissue (Figure 
3.37a). The intensity plot (Figure 3.37c) confirmed diffusion in the longitudinal direction, and 
the surface plot (Figure 3.37d) showed high distribution of FG2 488 CASE throughout the 
entire tissue. Figure 3.38 illustrate how FG2 488 CASE in a 10% PEG200 vehicle was 
distributed in the tissue. Here, the highest fluorescence intensities were located in the SC and 
in the laser cavities (Figure 3.38a). The distribution of fluorescence throughout the tissue 
(Figure 3.38 c, d) was generally lower compared to what was observed in Figure 3.37, 
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indicating a difference in diffusion efficiency in the two different skin tissues. Icorrected of 
FG2 488 CASE was detected to be 5538 ± 3185 when applied in a 60% DMSO vehicle, 
which was almost 2.5 times higher compared to the Icorrected of 2178 ± 1329 detected for the 
same sample applied in a 10% PEG200 vehicle.   
3.2.6.3. Summary of transdermal diffusion of fish gelatin peptides 
Figure 3.39 demonstrate a correlation between skin treatment and detected fluorescence 
(Icorrected) in the tissues for FG24 488 CASE in a 10% PEG200 vehicle (blue). The lowest 
mean fluorescence intensity was observed in untreated skin, and Icorrected was detected to be 
almost three times higher in skin pre-treated with micro-needles and eight times higher in skin 
pre-treated with L1. Almost a threefold higher Icorrected was detected in skin pre-treated with 
L1 compared to micro-needles for the same sample. A similar correlation was not observed 
for FG24 488 CASE applied in a 60% DMSO vehicle (green), where Icorrected was detected to 
be close to equal in untreated skin and skin pre-treated with micro-needles. However, Icorrected 
obtained from skin pre-treated with laser was four and five times higher compared to Icorrected 
detected in untreated skin and skin pre-treated with micro-needles, respectively.  
 
Figure 3.39: Icorrected values for FG24 488 CASE applied on skin in a 60% DMSO and a 10% 
PEG200 vehicle after diffusion into untreated and pre-treated skin.    
In untreated skin the FG24 488 CASE applied in a 60% DMSO was observed to result in a 
higher Icorrected compared to when applied in a 10% PEG200 vehicle (Figure 3.39). An 
interpretation of this could be that the 60% DMSO vehicle enabled diffusion deeper into the 
tissue, which may be supported by the minor increase in dermal fluorescence observed in the 
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surface plot for this tissue (Figure 3.27d). However, it would be expected a higher degree of 
accumulation in the SC for the sample in both vehicles, due to the molecular weight of the 
sample (discussed in section 3.2.5.3). This could indicate that a smaller amount of sample was 
available for diffusion into the skin. A reason for this could be an incline of the Franz-cells 
during incubation, causing some of the sample to run off from the center of the application 
chamber. Such an experimental weakness could also explain why Icorrected for FG24 488 
CASE, applied in a 60% DMSO vehicle, was lower in skin pre-treated with micro-needles 
compared to in untreated skin. Thus, it could also be a potential reason for the difference in 
Icorrected in the tissues pre-treated with micro-needles, where the value was almost a threefold 
higher for FG24 488 CASE applied in a 10% PEG200 vehicle. Varying degree of barrier 
disruption by the micro-needle device may also have affected the diffusion of the sample in 
the two skin tissues, and thus, contributed to the difference observed for the sample when 
applied in the two different vehicles.  
From the results in Figure 3.39 it was concluded that L1 to a larger extent enhanced the 
diffusion of FG24 488 CASE into human skin compared to micro-needles.  This was 
supported by the fluorescence intensities detected in the receptor phase, illustrated in figure 
3.40. Pre-treatment with micro-needles resulted in increased IRP values compared to untreated 
skin for both vehicles. Diffusion of FG24 488 CASE in a 10% PEG200 vehicle into skin, after 
pretreatment with L1, resulted in an IRP corrected value corresponding to ~73% of IRP max. This 
value was almost twenty-four times higher compared to the one detected after pretreatment 
with micro-needles. When 60% DMSO was used as vehicle, pretreatment with L1 resulted in 
an IRP corrected value almost fourteen times higher compared to micro-needles, a value 
corresponding to 13% of IRP max. From this it was concluded that L1 not only enabled the most 
efficient diffusion of FG24 488 CASE into the skin, but also all the way through the tissue, 
compared to diffusion in untreated skin and skin pre-treated with micro-needles.  
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Figure 3.40: IRP corrected values for FG24 488 CASE applied on skin in both the 60% DMSO 
and the 10% PEG200 vehicle after diffusion into untreated and pre-treated skin.    
In all the pre-treated tissues the highest Icorrected values were observed for FG24 488 applied in 
a 10% PEG200 vehicle. This was the opposite of what was found in the untreated skin tissues, 
and could indicate that after overcoming the SC barrier, the sample diffused more efficiently 
deeper in the skin, when applied in a PEG200 vehicle. The variations in Icorrected and IRP of 
FG24 488 CASE in the laser treated skin tissues may also be due to the fact that the tissues 
originated from two different donors (B and K), and that the difference in skin thickness was 
0.89 mm (Table 3.6). This could explain the lower diffusion efficiency observed for 
FG24 488 CASE when applied on skin tissue from donor B in a 60% DMSO vehicle, as 
discussed in subsection 3.2.5.3. Variations in distribution, Icorrected and IRP of FG24 488 CASE 
in tissues with the same pre-treatments may also have been due to the heterogeneity of the 
skin tissues, the independency between each single experiment, and experimental errors, also 
discussed in subsection 3.2.5.3.        
Figure 3.41 demonstrates a correlation between skin treatment and the Icorrected for FG2 488 
CASE detected in the different tissues. The lowest Icorrected was observed in untreated skin for 
both vehicles. For the sample applied in a 60% DMSO vehicle, Icorrected was observed to 
increase with factors of four and fourteen after pretreatments with micro-needles and L1, 
respectively. After diffusion of FG2 488 CASE applied in a 10% PEG200 vehicle into skin 
with the same pretreatments, Icorrected was detected to be approximately two and four times 
higher.  
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Figure 3.41: Icorrected values for FG2 488 CASE applied on skin in both the 60% DMSO and 
the 10% PEG200 vehicle after diffusion into untreated and pre-treated skin.  
From the results presented for FG2 488 CASE (Figures 3.33 and 3.34) it was concluded that 
the sample was unable to passively penetrate the SC barrier in untreated skin and diffuse 
deeper into the tissues. This was probably due to the molecular weight of the sample, which is 
in accordance with the size limitations in passive absorption through untreated skin, reported 
by Bos and Meinardi (2000) and discussed in subsection 3.2.5.3. The molecular weight may 
also have been the reason for the low extent of FG2 488 CASE distribution in deeper skin 
layers after pre-treatment with micro-needles. This pretreatment should in theory allow for 
larger molecules to diffuse through the SC and deeper into the skin, but efficient diffusion 
was not observed. This may further indicate a lower diffusion rate of this peptide sample 
compared to smaller peptides, such as FG24 488 CASE, and reflects the potential need for 
longer incubation time with increasing molecular size to achieve increased dermal 
distribution, also discussed in section 3.2.5.3. This is in accordance with that Mw have been 
found to be the main determinant for the maximum delivery or flux of drug solutions into and 
through human skin, as reported by Magnusson et.al (2004).  
One interpretation of the Icorrected detected in the laser treated tissues was that FG2 488 CASE 
applied in a 60% DMSO vehicle diffused more efficiently compared to the same sample in a 
10% PEG200 vehicle. However, this interpretation was contradictory to the results from the 
fluorescence measurements in the receptor phase, given in Figure 3.42, where a higher IRP 
value was obtained for the sample applied in a 10% PEG200 vehicle. Therefore, when these 
two results were interpreted collectively it was clear that FG2 488 CASE in a 10% PEG200 
vehicle diffused into and through the skin tissue with a higher rate compared to diffusion in a 
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60% DMSO vehicle. The higher diffusion rate caused a larger amount of sample to diffuse all 
the way through the tissue and into the receptor phase, and thus, could be the reason why a 
smaller amount was distributed in the tissue. The two different vehicles are further evaluated 
in section 3.2.9. In addition, the heterogeneity of the tissues, the independency between each 
of the experiments, and experimental errors, discussed in subsection 3.2.5.3, may have 
contributed to the variations in skin diffusion through the laser treated tissues. These factors 
may also have influenced the results obtained from untreated skin and skin pre-treated with 
micro-needles.  
 
Figure 3.42: IRP corrected values for FG2 488 CASE applied on skin in both the 60% DMSO 
and the 10% PEG200 vehicle after diffusion into untreated and pre-treated skin. 
The IRP corrected values of FG2 488 CASE for both vehicles after diffusion in untreated skin 
were very low, and may primarily have been a result of cellular components giving rise to 
autofluorescence. Pre-treatment with micro-needles resulted in increased IRP values compared 
to untreated skin for both the 60% DMSO and the 10% PEG200 vehicle. In the tissues pre-
treated with L1 diffusion of the sample in a 10% PEG200 vehicle resulted in an IRP corrected 
value corresponding to 25% of IRP max, a value nineteen times higher compared to the one 
detected after pretreatment with micro-needles. For the same pretreatment the sample applied 
in a 60% DMSO vehicle resulted in an IRP corrected value almost six times higher compared to 
after pretreatment with micro-needles, a value corresponding to ~18 % of IRP max.  
From the results after transdermal diffusion of FG2 488 CASE, it was concluded that L1 
enhanced the diffusion of the sample into human skin to a larger extent compared to micro-
needles, which was the same conclusion drawn for FG24 488 CASE. These skin 
pretreatments are further evaluated in section 3.2.10. A final remark must be made to 
40 
1540 
10934 
34 914 
29314 
0 
5000 
10000 
15000 
20000 
25000 
30000 
35000 
Untreated Pre-treated 
Micro-needles 
Pre-treated 
L1 
I R
P
 c
o
r
re
c
te
d
 
Skin treatment 
60% DMSO 
10% PEG200 
102 
 
emphasize the effect of Mw on transdermal diffusion of FG peptides. From the presented 
results Mw was determined to be the predominant reason for the generally lower distribution 
and Icorrected and IRP corrected values (the Icorrected values was of course also influenced by DOL) of 
FG2 488 CASE compared to FG24 488 CASE, regardless of vehicles and skin treatments. 
3.2.7. Diffusion experiments – G-block oligomers  
The two G-block oligomers G-DP18 and G-DP22 were used to study the diffusion of 
polysaccharides into the skin. Diffusion of each sample was studied in a total of 4 
experiments. Two different vehicles, 60% DMSO and 10% PEG200, were used separately to 
investigate the diffusion through untreated skin and through skin pre-treated with micro-
needles. The skin tissues were obtained from different donors (Table 2.3). The results from 
the transdermal diffusion experiments of G-DP18 488 HSS and G-DP22 488 HSS are given in 
subsection 3.2.7.1 and 3.2.7.2, respectively, and both are summarized in subsection 3.2.7.3.  
3.2.7.1. G-DP18 
Transdermal diffusion of G-DP18 488 HSS in untreated skin 
The results obtained from transdermal diffusion of G-DP18 488 HSS in a 60% DMSO vehicle 
into untreated skin from donor I and in a 10% PEG200 vehicle into untreated skin from donor 
G, are given in Figures 3.43 and 3.44, respectively.  
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Figure 3.43: Results of transdermal diffusion by G-DP18 488 HSS in a 60% DMSO vehicle 
into untreated skin from donor I. a) CLSM image showing the fluorescence intensity in the 
tissue, b) transillumination image showing the tissue structure, c) intensity plot with 
fluorescence intensity as a function of tissue depth and d) 3D surface plot illustrating the 
distribution of the G-DP18 sample in the tissue. 
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Figure 3.44: Results of transdermal diffusion by G-DP18 in a 10% PEG200 vehicle into 
untreated skin from donor G. a) CLSM image showing the fluorescence intensity in the tissue, 
b) transillumination image showing the tissue structure, c) intensity plot with fluorescence 
intensity as a function of tissue depth and d) 3D surface plot illustrating the distribution of the 
G-DP18 sample in the tissue.  
Figure 3.43 demonstrates how G-DP18 488 HSS in a 60% DMSO vehicle was distributed in 
the tissue after diffusion. From the CLSM image (Figure 3.43a) high intensity fluorescence 
was observed in the SC. The intensity and surface plots (Figure 3.43 c, d) confirmed this 
observation, and indicated a minor distribution of fluorescence deeper in the tissue. This 
dermal distribution was interpreted to be caused by endogenous fluorophores resulting in 
autofluorescence, rather than diffusion of FG2 488 CASE. Icorrected of the sample, detected to 
be 4883 ± 6646, was concluded to be a result of the accumulation of G-DP18 488 in the SC. 
Figure 3.44 illustrated similar results after diffusion of G-DP18 488 HSS in a 10% PEG200 
vehicle and Icorrected was detected to be 4944 ± 6571. However, the intensity plot (Figure 
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3.44c) illustrated lower fluorescence intensities in the SC, which could indicate that a smaller 
amount of the sample in a 10% PEG200 vehicle had penetrated into the SC. But the observed 
lower fluorescence intensities should not result in a higher Icorrected. The opposite was observed 
from the surface plot (Figure 3.44d), giving rise to inconsistent results. This inconsistency 
could be explained by comparing the CLSM and transillumination images in Figure 3.44, 
which clearly demonstrate that excess sample is located on the surface of the skin tissue. The 
fluorescence from this excess was believed to cause a faulty high Icorrected value and contribute 
to the high fluorescence intensities observed in the outermost layer of the tissue in the surface 
plot.  
Transdermal diffusion of G-DP18 488 HSS in skin pre-treated with micro-needles 
The results obtained from transdermal diffusion of G-DP18 488 HSS in a 60% DMSO vehicle 
into skin from donor I and in a 10% PEG200 vehicle into skin from donor G, after 
pretreatment with micro-needles, are given in Figures 3.45 and 3.46, respectively. 
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Figure 3.45: Results of transdermal diffusion by G-DP18 in a 60% DMSO vehicle into skin 
from donor I, after pretreatment with micro-needles. a) CLSM image showing the 
fluorescence intensity in the tissue, b) transillumination image showing the tissue structure, c) 
intensity plot with fluorescence intensity as a function of tissue depth and d) 3D surface plot 
illustrating the distribution of the G-DP18 sample in the tissue.  
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Figure 3.46: Results of transdermal diffusion by G-DP18 in a 10% PEG200 vehicle into skin 
from donor G, after pretreatment with micro-needles. a) CLSM image showing the 
fluorescence intensity in the tissue, b) transillumination image showing the tissue structure, c) 
intensity plot with fluorescence intensity as a function of tissue depth and d) 3D surface plot 
illustrating the distribution of the G-DP18 sample in the tissue.  
Figure 3.45 demonstrates how G-DP18 488 HSS in a 60% DMSO vehicle was distributed in 
the tissue after diffusion. High intensity fluorescence was observed to be evenly distributed in 
the SC (Figure 3.45a). The intensity and surface plots (Figure 3.45 c, d) confirmed this 
observation, and also indicated a minor distribution deeper into the tissue, primarily in the 
upper dermis. Icorrected of G-DP18 HSS in a 60% DMSO vehicle was detected to be 5002 ± 
5820, a value considerably lower compared to Icorrected, detected to be 9239 ± 6280, for the 
same sample in a 10% PEG200 vehicle. The results after diffusion of G-DP18 488 HSS in the 
PEG200 vehicle, presented in Figure 3.46, illustrated that the highest fluorescence intensities 
were unevenly distributed in the SC. The intensity plot (Figure 3.46c) supported this 
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observation, but also indicated diffusion of G-DP18 488 HSS deeper into the tissue. This was 
in accordance with the fluorescence distribution observed in the surface plot (Figure 3.46d).     
3.2.7.2. G-DP22 
Transdermal diffusion of G-DP22 488 HSS in untreated skin 
The results obtained from transdermal diffusion of G-DP22 488 HSS in a 60% DMSO vehicle 
into untreated skin from donor I and in a 10% PEG200 vehicle into untreated skin from donor 
G, are given in Figures 3.47 and 3.48, respectively.  
 
a) 
 
b) 
 
 
 
c)   d) 
Figure 3.47: Results of transdermal diffusion by G-DP22 in a 60% DMSO vehicle into 
untreated skin from donor I. a) CLSM image showing the fluorescence intensity in the tissue, 
b) transillumination image showing the tissue structure, c) intensity plot with fluorescence 
intensity as a function of tissue depth and d) 3D surface plot illustrating the distribution of the 
G-DP22 sample in the tissue. 
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c)   d) 
Figure 3.48: Results of transdermal diffusion by G-DP22 in a 10% PEG200 vehicle into 
untreated skin from donor G. a) CLSM image showing the fluorescence intensity in the tissue, 
b) transillumination image showing the tissue structure, c) intensity plot with fluorescence 
intensity as a function of tissue depth and d) 3D surface plot illustrating the distribution of the 
G-DP22 sample in the tissue. 
Figure 3.47 demonstrates how G-DP22 488 HSS in a 60% DMSO vehicle was distributed in 
the tissue after diffusion. High intensity fluorescence was observed to be distributed only in 
the SC (Figure 3.47a). Icorrected of the sample was detected to be 2866 ± 5318, and was 
assumed to be a result of the accumulation of fluorescence in the SC barrier. The results after 
diffusion of G-DP22 488 HSS in a 10% PEG200 vehicle, presented in Figure 3.48, illustrated 
a similar trend of fluorescence only being observed in the SC. However, the distribution of 
fluorescence intensities throughout the barrier was more uneven and Icorrected was detected to 
be 2226 ± 3625. Extended distribution of high fluorescence was observed in one specific area 
of the SC, which can be seen in the lower left corner of the CLSM image (Figure 3.48a). In 
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the same area the SC was observed to display a darker region in the transillumination image 
(Figure 3.48b), indicating overlapping or compressed tissue. This could result in falsely high 
fluorescence intensities.      
Transdermal diffusion of G-DP22 488 HSS in skin pre-treated with micro-needles 
The results obtained from transdermal diffusion of G-DP22 488 HSS in a 60% DMSO vehicle 
into skin from donor I and in a 10% PEG200 vehicle into skin from donor G after 
pretreatment with micro-needles, are given in Figures 3.49 and 3.50, respectively. 
 
a) 
 
b) 
 
c)   d) 
Figure 3.49: Results of transdermal diffusion by G-DP22 in a 60% DMSO vehicle into skin 
from donor I, after pretreatment with micro-needles. a) CLSM image showing the 
fluorescence intensity in the tissue, b) transillumination image showing the tissue structure, c) 
intensity plot with fluorescence intensity as a function of tissue depth and d) 3D surface plot 
illustrating the distribution of the G-DP22 sample in the tissue. 
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Figure 3.50: Results of transdermal diffusion by G-DP22 in a 10% PEG200 vehicle into skin 
from donor G, after pretreatment with micro-needles. a) CLSM image showing the 
fluorescence intensity in the tissue, b) transillumination image showing the tissue structure, c) 
intensity plot with fluorescence intensity as a function of tissue depth and d) 3D surface plot 
illustrating the distribution of the G-DP22 sample in the tissue.  
Figure 3.49 demonstrates the distribution of G-DP22 488 HSS applied in a 60% DMSO 
vehicle after the diffusion experiment. High intensity fluorescence was observed to be 
distributed throughout the SC (Figure 3.49a), and this observation was confirmed by the 
intensity and surface plots (Figure 3.49 c, d). From the CLSM image and the two plots it was 
also observed distribution of fluorescence deeper in the tissue, and Icorrected was detected to be 
6290 ± 4679. Diffusion of G-DP22 488 HSS in a 10% PEG200 vehicle was observed to result 
in a more uneven and lower distribution of fluorescence throughout the SC (Figure 3.50a).  
Icorrected of the sample applied in this vehicle was detected to be 5219 ± 3990, which was lower 
compared for the sample applied in a 60% DMSO vehicle. However, the extent of dermal 
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distribution of the sample was observed to be close to equal in the tissues regardless of the 
vehicle used and the difference in detected Icorrected values (Figures 3.49d and 3.50d).      
3.2.7.3. Summary of transdermal diffusion of G-block oligomers  
Figure 3.51 demonstrates the difference in Icorrected for G-DP18 488 HSS in untreated and pre-
treated skin when applied in the two different vehicles. The Icorrected for G-DP18 488 HSS in a 
60% DMSO vehicle was almost the same in both untreated skin and skin pre-treated with 
micro-needles, and little difference was detected in untreated skin for the sample regardless of 
the vehicle used. However, a profound difference in Icorrected was detected for G-DP18 488 
HSS after pre-treatment with micro-needles, as the Icorrected value was almost a twofold higher 
for the sample applied in a 10% PEG200 vehicle compared to in a 60% DMSO vehicle. Thus, 
the same difference was observed between untreated skin and skin pre-treated with micro-
needles for the sample in a 10% PEG200 vehicle. From the results in untreated skin (Figures 
3.43 and 3.44) it was concluded that G-DP18 488 HSS was unable to penetrate the SC and 
diffuse deeper into the tissues during the 22 hours of incubation. The IRP values, given in 
Figure 3.52, did not indicate diffusion through untreated skin either, and the conclusion was 
considered to be plausible.  
 
Figure 3.51: Icorrected values for G-DP18 488 HSS applied on skin in both the 60% DMSO and 
the 10% PEG200 vehicle after diffusion into untreated and pre-treated skin.  
G-DP18 488 HSS in a 60% DMSO vehicle resulted in a similar Icorrected in both untreated and 
pre-treated skin. By comparing the surface plots of the two tissues (Figures 3.43d and 3.45d), 
it was determined that distribution of the sample was observed in the epidermis and the upper 
dermis in the tissue pre-treated with micro-needles. Weak fluorescence was also observed 
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deep in the untreated tissue, but this was believed to mainly be caused by autofluorescence. 
This indicated that the micro-needles enhanced the penetration through the SC, and allowed 
for the sample to diffuse deeper down. This was also confirmed by the IRP corrected values, 
though both values were low relative to IRP max. Applied on skin pre-treated with micro-
needles, G-DP18 488 HSS in this vehicle resulted in an IRP corrected value corresponding to ~7% 
of IRP max, while the value corresponded to ~2% of IRP max when applied on untreated skin. G-
DP18 488 HSS applied in a 10% PEG200 vehicle resulted in the highest IRP corrected value 
(Figure 3.52). But this value only corresponded to 3% of IRP max, which once again illustrated 
that a higher dermal distribution was not equivalent with diffusion of the sample all the way 
through the tissue. However, it was concluded that micro-needles enhanced diffusion of G-
DP18 488 HSS into human skin.          
 
Figure 3.52: IRP corrected values for G-DP18 488 HSS applied on skin in both the 60% DMSO 
and the 10% PEG200 vehicle after diffusion into untreated and pre-treated skin. 
The difference in Icorrected observed in tissues pre-treated with micro-needles was profound. 
This difference could be due to the two different vehicles and varying degree of barrier 
disruption by the micro-needle device, as already emphasized for the experiments performed 
with FG peptides (subsection 3.2.6.3). An uneven distribution of G-DP18 488 HSS in a 10% 
PEG200 vehicle compared to the distribution of the same sample in a 60% DMSO vehicle 
was observed in skin tissues pre-treated with micro-needles (Figures 3.45a and 3.46a). The 
uneven distribution could be due to a more effective penetration enhancement by the micro-
needles in this tissue, enabling more of the sample to diffuse through the SC barrier. This 
explanation may be supported by the observed increase in dermal distribution (Figure 3.46d). 
A similar distribution was also observed for FG24 488 CASE (Figure 3.28) and an 
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experimental weakness regarding the Franz-cell was suggested to be one possible cause, as 
discussed in subsection 3.2.6.3. However, this would mean that the difference in Icorrected 
would have been even higher if larger amounts of G-DP18 488 HSS in the 10% PEG200 
vehicle were located in the center of the application chamber during incubation.  
Figure 3.53 demonstrates a correlation between the detected Icorrected and skin treatment for G-
DP22 488 HSS. Similar as for FG2 488 CASE, the lowest Icorrected was observed in untreated 
skin tissues. Icorrected was observed to be approximately a twofold higher in skin pre-treated 
with micro-needles compared to in untreated skin for the sample in both vehicles.      
 
Figure 3.53: Icorrected values for G-DP22 488 HSS applied on skin in both the 60% DMSO and 
the 10% PEG200 vehicle after diffusion into untreated and pre-treated skin. 
From the results presented for G-DP22 488 HSS it was concluded that the sample was unable 
to penetrate the SC barrier in untreated skin and diffuse deeper into the tissue, regardless of 
the vehicle used (Figures 3.47 and 3.48). The Icorrected values were therefore believed to be a 
result of the accumulation of the sample in the SC. The low IRP corrected values obtained from 
these two experiments, given in Figure 3.54, supported this conclusion and thus confirmed 
that the sample was unable to diffuse into and through untreated skin regardless of the vehicle 
used. It was further concluded that G-DP22 488 HSS diffused into skin pre-treated with 
micro-needles, a conclusion based on the results, presented in Figures 3.49 and 3.50, and the 
increased Icorrected values in these tissues compared to in the untreated skin tissues. However, 
the IRP corrected values indicated that the diffusion of the sample applied in a 60% vehicle 
occurred at a higher rate compared to when applied in a 10% PEG200 vehicle, as these values 
corresponded to 11% and 2% of IRP max, respectively. 
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Figure 3.54: IRP corrected values for G-DP18 488 HSS applied on skin in both the 60% DMSO 
and the 10% PEG200 vehicle after diffusion into untreated and pre-treated skin. 
A trend of higher Icorrected values obtained for G-DP22 488 HSS applied in a 60% DMSO 
vehicle was observed (Figure 3.53). The differences in Icorrected in tissues with the same skin 
treatment could be due to the two vehicles used, and in skin pre-treated with micro-needles a 
varying degree of barrier disruption may have contributed to the observed differences. The 
vehicles and skin pretreatments will be further evaluated in section 3.2.9 and 3.2.10, 
respectively. However, the dermal distribution, both in regards to extent and fluorescence 
intensities, of the sample in both vehicles (Figures 3.49d and 3.50d) was very similar. 
Variations in distribution, Icorrected, and IRP of the G-block oligomers in tissues with the same 
pre-treatments may also be due to the heterogeneity of the skin tissues, the independency 
between each single experiment and experimental errors, discussed in subsection 3.2.5.3. 
The skins in the experiments performed with G-DP18 488 HSS and G-DP22 488 HSS 
originated from two different donors (G and I). The possible effect of difference in skin 
thickness on diffusion efficiency has already been discussed in subsection 3.2.5.3. The 
thickness of the skins from donor G and I was almost equal (Table 3.6), the difference was 
only 0.01 mm. Therefore, the impact of this difference was believed to be minimal. However, 
the tissues may have possessed even higher degrees of heterogeneity compared to tissues from 
one individual donor. This may have contributed to the difference observed between the G-
block oligomer samples applied in a 60% DMSO and a 10% PEG200 vehicle in both 
untreated and pre-treated skin.  
Earlier in this subsection it was concluded that both G-DP18 488 HSS and G-DP22 488 HSS 
was unable to penetrate the SC and diffuse deeper into untreated skin tissues. This was 
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interpreted to be due to the molecular weight of the samples, and was in accordance with the 
“500 Dalton rule” introduced by Bos and Meinardi (2000) and discussed in subsection 3.2.5.3. 
It should be remarked that this interpretation was based on the samples Mn and not Mw, as for 
the FG peptides. However, Mw was expected to be higher compared to Mn for the oligomers, 
making the assumption plausible.  
3.2.8. Evaluation of the model drugs 
Of the two FG peptides, FG24 488 CASE displayed the highest Icorrected values regardless of 
pretreatments performed on the skins (section 3.2.6.3). A similar trend was observed for the 
G-block oligomers, where G-DP18 488 HSS generally displayed the highest Icorrected values, 
indicating that the molecular size of the model drugs was determining for the efficiency of 
skin diffusion. These observations were in accordance with molecular weight being the main 
determinant for diffusion across skin (Magnusson et al., 2004), and the size limitations in skin 
absorption reported by Bos and Meinardi (2000), already discussed in subsection 3.2.5.3. The 
impact of molecular weight was also likely to be decisive for the low Icorrected values obtained 
after diffusion of FG2 into skin. However, FG24 488 CASE applied in a 60% DMSO vehicle 
was suggested to have diffused deeper into untreated skin. A possible cause for this could be 
the polydispersity of the test sample, meaning that molecules with a lower Mw than the 
estimated average may have been able to diffuse through the SC and deeper into the skin. 
Interestingly, the Icorrected values of G-DP18 488 HSS were higher compared to for FG24 488 
CASE, which also were contradictory to the reported effect of molecular weight on 
transdermal diffusion. However, this contradiction may be a result of the underestimation of 
DOL for the G-block samples (section 3.1.5), which consequently resulted in an 
overestimation of Icorrected, and thus falsely high mean fluorescence intensities in the tissues. It 
should also be taken into consideration that FG24 488 CASE generally resulted in more 
extended distribution in the dermal skin layer compared to G-DP18 488 HSS.    
High Icorrected values of G-DP18 and G-DP22 could indicate enhanced transdermal delivery 
similar to the enhancement of mucosal drug delivery, reported by Taylor and Draget (2011) 
(section 1.5.2.) A potential enhancement effect of G-block would, however, be restricted to 
the extracellular matrix (ECM) in the deeper skin layers and thus, G-blocks would first need 
to efficiently penetrate the SC. From the surface plots (subsections 3.2.7.1 and 3.2.7.2), no 
distribution of G-DP18 and G-DP22 were observed deeper in the tissue in untreated skin, and 
in skin pre-treated with micro-needles a greater dermal distribution was observed for 
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FG24 488 CASE (subsection 3.2.6.1) compared to the two G-block samples (subsections 
3.2.7.1 and 3.2.7.2).     
The G-block samples were also observed to result in higher fluorescence intensities and more 
extended accumulation in the SC, compared to the FG peptides. A possible interpretation of 
these observations could be that FG peptides diffused into skin more efficiently compared to 
G-block oligomers. FG peptides display a weak net positive charge at physiological pH and 
possess an amphiphilic nature due to their content of both hydrophilic and hydrophobic amino 
acids. Under identical conditions, the hydrophilic G-block oligomers are polyanionic. 
Therefore, a higher diffusion efficiency would be expected for the FG peptides across the 
hydrophobic skin barrier, since molecules with hydrophobic properties are reported to diffuse 
more efficiently through the barrier compared to hydrophilic molecules (Bos and Meinardi, 
2000). The more extended and rigid conformation of G-block oligomers compared to the 
more flexible FG peptides may also have influenced the diffusion efficiency. However, 
neither of the model drugs fit into the ideal drug characteristics suggested for successful 
transdermal delivery (section 1.3), and their varying properties was one of the reason for 
choosing them as model drugs.    
Theoretically, the diffusion of charged FG peptides and G-blocks may be affected by 
electrostatic interactions in the deeper skin layers. Negatively charged components in the 
ECM could restrict the entry of negatively charged G-block molecules, but if these molecules 
were able to enter the matrix, electrostatic repulsion could also efficiently move them into the 
receptor phase. The net positive charge of the FG peptides could cause them to be retained 
due to electrostatic attraction, and thus limit diffusion deeper into and through the skin. From 
the results presented in this report it was difficult to determine the exact impact of the charged 
nature of the model drugs, and the effect of size and degree of barrier disruption, was 
considered to have a larger impact on transdermal diffusion.   
3.2.9. Evaluation of the vehicles 
60% DMSO and 10% PEG200 was applied as vehicles for the model drugs in the transdermal 
diffusion experiments. DMSO and PEG are both classified as chemical enhancers, which are 
known to reduce the barrier properties of the SC and increase skin permeability (section 1.3). 
The use of known chemical enhancers as vehicles could potentially enhance the diffusion of 
the test samples into untreated skin or contribute to a synergistic enhancement effect in the 
pre-treated skin tissues.  
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From the results of the transdermal diffusion experiments a general trend of higher Icorrected in 
the tissues was observed for FG24 488 CASE and G-DP18 488 HSS applied in a 10% 
PEG200 vehicle. The opposite trend was observed for FG2 488 CASE and G-DP22 488 HSS, 
and could possibly indicate a correlation between molecular weight and enhancement effect 
by the vehicles. However, even though higher dermal distribution was obtained for FG2 488 
CASE in a 60% DMSO vehicle, the IRP value for the sample in a 10% PEG200 vehicle was 
higher, indicating more efficient diffusion of the sample in this vehicle. The highest IRP values 
(also relative to IRP max), were observed for FG2 488 CASE and FG24 488 CASE in 10% 
PEG200, after diffusion through laser treated skin, and this could further support the 
indication of more efficiently diffusion of the samples in this vehicle. PEG is categorized in 
the chemical enhancement group of alcohols, which enhance skin permeability through a 
variety of mechanisms, including extraction of lipids and improvement of drug partitioning 
into the skin.   
The partition coefficient (P) will be determined by the properties of both the drug and the 
vehicle (section 1.4), and an increase of P is known to increase the skin permeability. For 
successful transdermal delivery, moderate lipophilicity (log P 1-3) is suggested as one of the 
ideal characteristics of the compound to be delivered (section 1.3). The partition coefficients 
of solute between the vehicles and the skin for the model drugs were not known in this study. 
However, it was believed that the vehicles would have a higher affinity for the SC compared 
to the model drugs. This could further alter the partition coefficient of the model drugs and 
potentially enable them to diffuse in this skin layer. Deeper in the tissues it was likely that the 
drugs possessed a higher affinity for the ECM and thus, could diffuse into and be distributed 
in the matrix and potentially be taken up in the blood stream.     
The vehicles were not observed to result in profound differences, or increase, in Icorrected (as a 
result of dermal distribution) in the untreated skin tissues, indicating that the vehicles alone 
were not able to enhance the diffusion of the model drugs into skin. This further made it 
difficult to conclude which of the vehicles that were most suited for transdermal delivery of 
the model drugs. However, the highest Icorrected and IRP were observed in tissues where 10% 
PEG200 was used as vehicle. Further, PEG is non-toxic and non-immunogenic and already 
known to be used in pharmaceutical applications such as dermal ointments and creams 
(section 1.3), indicating compatibility with the skin. This makes PEG200 to an appealing 
choice of vehicle. DMSO, on the other hand, can cause rash and skin irritations (section 1.3) 
and has been shown to be toxic to the keratinocytes in the skin at constant exposure of high 
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concentrations (Aspevik, 2010). But regardless of all this, the effect of the two different 
vehicles on transdermal diffusion should be further studied before any conclusions are made.  
3.2.10. Evaluation of the effect of pretreatment 
The transdermal diffusion experiments revealed that the model drugs were unable to 
efficiently penetrate the SC and diffuse deeper into untreated skin. Micro-needles were 
observed to enhance transdermal diffusion of all the test samples. However, the need for 
manual operation of the micro-needle device made it difficult to achieve an identical and 
constant pressure for each pretreatment. Thus, a standardized method for skin penetration 
enhancement by micro-needles, resulting in consistent depths of penetration in each of the 
skin tissues, was difficult to obtain.  
Laser treatment (L1, Table 2.2) was included in the transdermal diffusion experiments to 
obtain a highly standardized enhancement method. The laser created penetration patterns, 
where the density of laser spots, the distance between spots, and spot depth and diameter were 
identical in all the tissues after this pretreatment was performed. This penetration 
enhancement not only allowed distribution of FG peptides throughout the skin tissues, but 
also enabled efficient diffusion all the way through the tissues. FG2 488 CASE, with an 
estimated average Mw of 8000 g/mol, was observed to diffuse into and through the skin 
tissues pre-treated with L1. The Mw of this sample was 16 times higher than the Mw of 500 
Dalton introduced by Bos and Meinardi (2000) as the limit value for passive diffusion into 
untreated skin, which illustrated the profound effect of this pretreatment. Diffusion of 
FG24 488 CASE in laser treated skin resulted in the highest Icorrected and IRP corrected (also 
relative to IRP max). However, transdermal diffusion of G-block oligomers was not studied in 
laser treated skin, and comparison between the oligomers and the peptides could only be made 
for untreated skin and skin pre-treated with micro-needles.   
The penetration enhancement techniques used in the transdermal diffusion experiments 
showed enhancing effects in vitro, but they are not easily transferable for use in in vivo 
experiments or treatments. Micro-needles have been introduced as a promising approach to 
achieve increased skin permeability and transdermal delivery of drugs that otherwise would 
be restricted by the SC barrier. The micro-needles reported for in vivo use, such as in patches, 
only penetrates the SC and into the epidermis and are therefore not associated with pain or 
discomfort. However, the micro-needles used in the transdermal diffusion experiments were 
long enough to penetrate into the dermal layers of the skin, which could cause both pain and 
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bleeds if used on humans (Badran et al., 2009). The manufacturer also strongly emphasizes 
that the use of this micro-needle device should be performed by trained and licensed skin care 
professionals (Dermaroller, 2012). The laser treatment may cause a variety of adverse effects, 
including pain and burns. In addition, the apparatus used in such pretreatments are expensive, 
and treatment is restricted to clinical settings where it should be performed by professionals, 
as described in section 1.3.2. Taking all of this into account, both penetration enhancement 
techniques are likely to reduce patient compliance due to the risk of painful treatments, and 
laser treatments also exclude the possibility for self administering of drugs.   
3.3. Future prospects 
The FG peptides and G-block oligomers used as model drugs all demonstrated ability to 
diffuse in human skin, and it would therefore be of interest to further investigate these 
molecules as model drugs. It would also be preferable to perform each individual experiment 
more than once. It could also be advantageous to produce monodisperse test samples with the 
same molecular weights, as this would provide a better basis for comparison of the peptides 
and the oligomers. This could further make it possible to better evaluate the effect of the other 
physicochemical properties of the biopolymers on transdermal diffusion. It would also be of 
interest to perform studies to investigate the upper molecular weight limit for diffusion into 
and through pre-treated skin. 
If further transdermal diffusion studies are to be performed as in the work presented in this 
report, effort should be made to minimize the experimental weaknesses and risks of errors 
associated with the experimental set-up. Decline of the Franz-type diffusion cells during 
incubation should be prevented and a better system for removal of skin tissues from the 
diffusion cells after incubation should be introduced, to avoid spillage of fluorescently labeled 
sample molecules into the receptor phase.  
In this study physically penetration enhancement methods showed to have profound effect on 
transdermal diffusion. However, the micro-needles and laser treatments that were used are not 
readily transferable for use in in vivo. It was also found that the handhold micro-needle device 
resulted in varying degree of barrier disruption compared to the standardized laser treatment. 
It would therefore be beneficial to develop fully standardized penetration enhancement 
techniques, to enable efficient diffusion of molecules larger than 500 g/mol (Da) through the 
SC and deeper into the skin, which are readily transferable for use in in vivo transdermal drug 
delivery. 
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A step forward from studying transdermal diffusion in vitro could be to perform similar 
experiments in vivo, using experimental animals such as mice. This would especially be 
interesting for studying transdermal delivery of drugs for systemic effect. However, 
development of experimental assays for tracing of the model drugs in the bloodstream is 
required. In addition, animal experiments for research purposes must be licensed, which 
further requires a thoroughly elaborated experimental design.   
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4. Conclusion  
This study demonstrated that water soluble molecules were able to diffuse into skin when 
physically penetration enhancement techniques were used to overcome the skin barrier. The 
results from the transdermal diffusion experiments demonstrated that wM and degree of SC 
barrier disruption were the main determinants for successful diffusion of the model drugs into 
human skin. Of the four model drugs chosen for use in the experiments, the smallest FG 
peptide sample, with an estimated average molecular weight of 3000 g/mol, applied on laser 
pre-treated skin in a 10% PEG200 vehicle, resulted in the most efficient diffusion into and 
through human skin. Laser treatment was found to have the most profound enhancing effect 
on transdermal diffusion of FG peptides, as it enabled efficient diffusion both into and 
through the skin during the 22 hours of incubation introduced in the experiments. Micro-
needles enhanced diffusion of FG peptides and G-block oligomers into skin to a varying 
extent, and thus indicated varying degree of barrier disruption by this device. None of the 
model drugs demonstrated efficient diffusion into untreated skin, although the results for 
FG24 488 CASE might have indicated a minor dermal diffusion in the tissue. It was therefore 
concluded that the vehicles alone did not enhance diffusion through the SC. However, the 
most efficient diffusion of model drugs in pre-treated skin were detected for samples applied 
on skin in a 10% PEG200 vehicle. Taking into account that this compound is non-toxic and 
non-immunogenic, PEG may be considered to be more applicable as vehicle compared to 
DMSO, known to be a skin irritant and potentially toxic, in transdermal diffusion 
experiments.  
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Appendix A:  SEC-MALLS 
The weight average molecular weight (Mw) and the number average molecular weight (Mn) 
of fish gelatin (FG) peptides were determined by SEC-MALLS analyses (section 3.1.1). The 
analyses were performed by Ann-Sissel Teialeret Ulset, Staff Engineer at the Department of 
biotechnology, NTNU. The experimental procedure is given in section 2.2.3.1. The raw data 
from the analyses are given in this appendix.  
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Appendix B:  MALDI-TOF 
The weight average molecular weight (Mw) and the number average molecular weight (Mn) 
of fish gelatin (FG) peptides were determined by MALDI-TOF analyses (section 3.1.2). The 
analyses were performed by Kåre Andre Kristiansen, Senior Engineer at the Department of 
biotechnology, NTNU. The experimental procedure is given in section 2.2.3.2. The MALDI-
TOF spectra are given in this appendix, and the raw data are given on the enclosed CD. The 
mass spectra peaks are only labeled for FG4, FG12 and FG24. This is because labeling of the 
peaks in the other spectra caused overlapping values and made the results disorderly. 
B.1  FG1 
 
 
Figure B.1: MALDI-TOF spectrum for FG1. The x-axis and y-axis display the mass-to-
charge (m/z) ratio and intensity.  
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B.2  FG2 
 
 
Figure B.2: MALDI-TOF spectrum for FG2. The x-axis and y-axis display the mass-to-
charge (m/z) ratio and intensity.  
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B.3  FG4 
 
 
Figure B.3: MALDI-TOF spectrum for FG4. The x-axis and y-axis display the mass-to-
charge (m/z) ratio and intensity. The values in the spectrum indicate the molecular weight 
represented by the peaks. 
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Figure B.4: MALDI-TOF spectrum for FG6. The x-axis and y-axis display the mass-to-
charge (m/z) ratio and intensity.  
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B.5  FG8 
 
 
Figure B.5: MALDI-TOF spectrum for FG8. The x-axis and y-axis display the mass-to-
charge (m/z) ratio and intensity.  
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Figure B.6: MALDI-TOF spectrum for FG12. The x-axis and y-axis display the mass-to-
charge (m/z) ratio and intensity. The values in the spectrum indicate the molecular weight 
represented by the peaks. 
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Figure B.7: MALDI-TOF spectrum for FG16. The x-axis and y-axis display the mass-to-
charge (m/z) ratio and intensity.  
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Figure B.8: MALDI-TOF spectrum for FG18. The x-axis and y-axis display the mass-to-
charge (m/z) ratio and intensity.  
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B.9  FG20 
 
 
Figure B.9: MALDI-TOF spectrum for FG20. The x-axis and y-axis display the mass-to-
charge (m/z) ratio and intensity.  
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B.10  FG24 
 
 
Figure B.10: MALDI-TOF spectrum for FG24. The x-axis and y-axis display the mass-to-
charge (m/z) ratio and intensity. The values in the spectrum indicate the molecular weight 
represented by the peaks. 
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B.11  FG36 
 
 
Figure B.11: MALDI-TOF spectrum for FG36. The x-axis and y-axis display the mass-to-
charge (m/z) ratio and intensity.  
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Appendix C:  1H-NMR 
The Mn of G-DP18 and G-DP22 were determined from the results of the 
1
H-NMR analyses 
performed prior to this study (Eiken, 2011). The analysis resulted in two 
1
H-NMR spectra, 
one for G-DP18 and one for G-DP22, which are given in Figures C.1 and C.2, respectively. 
The fractions of G- and M monomers, and the number average degree of polymerization 
(DPn) given in Table C.1. 
C.1:   
1
H-NMR spectrum of G-DP18 
The 
1
H-NMR spectra of the G-block sample G-DP18. 
 
Figure C.1: 
1
H-NMR spectra of the G-block sample G-DP18, showing integral limits and 
corresponding values (Eiken, 2011).   
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C.2:  
1
H-NMR spectrum of G-DP22 
The 
1
H-NMR spectra of the G-block sample G-DP18. 
 
Figure C.2: 
1
H-NMR spectra of the G-block sample G-DP22, showing integral limits and 
corresponding values (Eiken, 2011).   
 
 
Table C.1: The number average degree of polymerization (DPn) and fractions of G and M 
monomers in the G-block samples G-DP18 and G-DP22 (Eiken, 2011)  
Sample FG 
(internal) 
FM FGG FMG 
FGM 
FMM FG 
(reduced) 
FG 
(total) 
DPn 
G-DP18 0.90 0.10 0.82 0.083 0.012 0.056 0.96 18 
G-DP22 0.92 0.08 0.85 0.070 0.007 0.045 0.97 22 
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Appendix D:  Absorbance values – DOL 
 
The degree of labeling (section 2.2.4) was calculated for the FG and G-block samples 
according to Equation 2.3. The Amax values for the samples, measured at the λmax of the 
respective dyes, are given in Table D.1. 
 
Table D.1: Amax measured for the FG peptides and G-block oligomers applied in transdermal 
diffusion experiments. The measured values were used to calculate the DOL of the samples.  
Sample Amax 
FG24 488 CASE 0.0076 
FG24 532 CASE 0.0042 
FG2 488 CASE 0.023 
G-DP18 488 HSS 0.0043 
G-DP22 488 HSS 0.0079 
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Appendix E:  Mean fluorescence intensity values - diffusion 
kinetics experiments 
 
The diffusion of Alexa 488 CASE and FG24 488 CASE, each in a 60% DMSO vehicle, was 
studied by varying the incubation time of tissues pre-treated with micro-needles and L1. 
These experiments were performed to investigate the time it would take for a sample to 
diffuse through the SC and further into deeper skin layers. The mean fluorescence intensity in 
the tissues (Imean tissue) and the Imean sample (Imean tissues corrected for Iauto) for Alexa 488 CASE, 
after diffusion into skin pre-treated with micro-needles and laser from donor E and F, are 
given in Table E.1 and E.2, respectively. Icorrected for FG24 488 CASE, after diffusion into 
skin pre-treated with micro-needles and laser, are given in Table E.2 and E.4, respectively. 
Table E.1: Imean-tissue and Imean-sample of Alexa 488 CASE in skin tissues pre-treated with 
micro-needles, from donor E and F, after 2-24 hours of incubation.    
Incubation time (hours) Imean-tissue Imean-sample 
2               26 ± 29 17 ± 19 
6             101 ± 64 92 ± 69 
12             138 ± 83                 115 ± 97 
16 79 ± 49 56 ± 63 
18 63 ± 35 40 ± 49 
20 85 ± 47 62 ± 61 
24 75 ± 40 52 ± 54 
 
Table E.2: Icorrected FG24 488 CASE in skin tissues pre-treated with micro-needles, from 
donor E and F, after 2-24 hours of incubation.    
Incubation time (hours) Icorrected 
2 2219 ± 3159 
6 2919 ± 3043 
12 5075 ± 3784 
16 8639 ± 4162 
18 6243 ± 2888 
20 4979 ± 3133 
24 4717 ± 2630 
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Table E.3: Imean-tissue and Imean-sample of Alexa 488 CASE in skin tissues pre-treated with laser 
(L1), from donor J, after 20 minutes-6 hours.    
Incubation time  Imean-tissue Imean-sample 
20 minutes 56 ± 84 43 ± 91 
40 minutes 69 ± 91 56 ± 98 
1 hour 90 ± 97                 77 ± 104 
2 hours                 111 ± 109                 98 ± 116 
6 hours               239 ± 47               226 ± 226 
 
Table E.4: Icorrected of FG24 488 CASE in skin tissues pre-treated with laser (L1), from donor 
J, after 20 minutes-6 hours.    
Incubation time  Icorrected 
20 minutes 2923 ± 6930 
40 minutes 5104 ± 9478 
1 hour 11093 ± 12392 
2 hours 13862 ± 13394 
6 hours 24724 ± 10621 
 
 
 
 
